Canopy Growth (CGC) 10-Q 9 Feb 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2020	Feb. 08, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	Canopy Growth Corporation
Entity Central Index Key	0001737927
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		376,840,247
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common shares, no par value
Trading Symbol	CGC
Security Exchange Name	NASDAQ
Entity File Number	001-38496
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	1 Hershey Drive
Entity Address, City or Town	Smith Falls
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	K7A 0A8
City Area Code	855
Local Phone Number	558-9333
Document Quarterly Report	true
Document Transition Report	false

Condensed Interim Consolidated

Condensed Interim Consolidated Balance Sheets (Unaudited) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Current assets:
Cash and cash equivalents	$ 824,960	$ 1,303,176
Short-term investments	768,564	673,323
Restricted short-term investments	11,426	21,539
Amounts receivable, net	93,673	90,155
Inventory	394,023	391,086
Prepaid expenses and other assets	78,979	85,094
Total current assets	2,171,625	2,564,373
Equity method investments	16,992	65,843
Other financial assets	682,595	249,253
Property, plant and equipment	1,148,338	1,524,803
Intangible assets	366,375	476,366
Goodwill	1,917,900	1,954,471
Other assets	5,357	22,636
Total assets	6,309,182	6,857,745
Current liabilities:
Accounts payable	86,463	123,393
Other accrued expenses and liabilities	88,419	64,994
Current portion of long-term debt	13,031	16,393
Other liabilities	160,306	215,809
Total current liabilities	348,219	420,589
Long-term debt	619,165	449,022
Deferred income tax liabilities	23,251	47,113
Other liabilities	157,079	190,660
Total liabilities	2,013,660	1,679,875
Commitments and contingencies
Redeemable noncontrolling interest	111,100	69,750
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 373,803,786 shares and 350,112,927 shares, respectively	6,787,725	6,373,544
Additional paid-in capital	2,509,678	2,615,155
Accumulated other comprehensive income	27,407	220,899
Deficit	(5,368,178)	(4,323,236)
Total Canopy Growth Corporation shareholders' equity	3,956,632	4,886,362
Noncontrolling interests	227,790	221,758
Total shareholders' equity	4,184,422	5,108,120
Total liabilities and shareholders' equity	6,309,182	6,857,745
Acreage
Current liabilities:
Liability arising from Acreage Arrangement	450,000	250,000
Warrant
Current liabilities:
Derivative liability	$ 415,946	$ 322,491

Condensed Interim Consolidate_2

Condensed Interim Consolidated Balance Sheets (Parenthetical) (Unaudited) - shares	Dec. 31, 2020	Mar. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, shares issued	373,803,786	350,112,927

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 169,907	$ 135,546	$ 439,823	$ 324,558
Excise taxes	17,379	11,782	41,613	33,699
Net revenue	152,528	123,764	398,210	290,859
Cost of goods sold	127,943	85,556	341,050	230,718
Gross margin	24,585	38,208	57,160	60,141
Operating expenses
Selling, general and administrative expenses	144,078	168,910	426,723	496,158
Share-based compensation	19,963	61,679	72,632	241,922
Expected credit losses on financial assets and related charges	13,735		108,480
Asset impairment and restructuring costs	400,422		459,579
Total operating expenses	578,198	230,589	1,067,414	738,080
Operating loss	(553,613)	(192,381)	(1,010,254)	(677,939)
Loss from equity method investments	(671)	(2,664)	(40,851)	(6,668)
Other income (expense), net	(290,567)	57,963	(21,106)	600,624
Loss before income taxes	(844,851)	(137,082)	(1,072,211)	(83,983)
Income tax recovery	(15,600)	(27,448)	(18,086)	(22,948)
Net loss	(829,251)	(109,634)	(1,054,125)	(61,035)
Net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interest	75,129	(18,280)	(9,183)	(42,730)
Net loss attributable to Canopy Growth Corporation	$ (904,380)	$ (91,354)	$ (1,044,942)	$ (18,305)
Basic and diluted loss per share	$ (2.43)	$ (0.26)	$ (2.83)	$ (0.05)
Basic and diluted weighted average common shares outstanding	372,908,767	348,530,622	369,418,037	346,877,660
Comprehensive (loss) income:
Net loss	$ (829,251)	$ (109,634)	$ (1,054,125)	$ (61,035)
Other comprehensive (loss) income, net of income tax effect
Fair value changes of own credit risk of financial liabilities	(30,090)	32,830	(82,560)	69,490
Foreign currency translation	(45,809)	1,122	(110,932)	(50,995)
Total other comprehensive (loss) income, net of income tax effect	(75,899)	33,952	(193,492)	18,495
Comprehensive loss	(905,150)	(75,682)	(1,247,617)	(42,540)
Comprehensive income (loss) attributable to noncontrolling interests and redeemable noncontrolling interest	75,129	(18,280)	(9,183)	(42,730)
Comprehensive (loss) income attributable to Canopy Growth Corporation	$ (980,279)	$ (57,402)	$ (1,238,434)	$ 190

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Shareholder's Equity (Unaudited) - CAD ($) $ in Thousands	Total	Common Shares	Additional Paid-in capitalShare-based Reserve	Additional Paid-in capitalWarrant	Additional Paid-in capitalOwnership Changes	Additional Paid-in capitalRedeemable Noncontrolling Interest	Accumulated Other Comprehensive Income (Loss)	Deficit	Noncontrolling Interests
Beginning balance at Mar. 31, 2019	$ 7,065,708	$ 6,029,222	$ 505,172	$ 1,589,925	$ (500,963)	$ (2,110)	$ (5,905)	$ (835,118)	$ 285,485
Other issuances of common shares and warrants	110	266,462	(266,711)	359
Exercise of warrants	446	932		(486)
Exercise of Omnibus Plan stock options	39,149	64,342	(25,193)
Share-based compensation	235,493		235,493
Issuance of replacement equity instruments	1,885		1,885
Issuance and vesting of restricted share units		1,289	(1,289)
Acreage warrant modification	(1,117,639)			1,049,153				(2,166,792)
Changes in redeemable noncontrolling interest	(12,467)					(8,924)			(3,543)
Ownership changes relating to noncontrolling interests	7,491				(156)				7,647
Comprehensive (loss) income	(42,540)						18,495	(18,305)	(42,730)
Ending balance at Dec. 31, 2019	6,177,636	6,362,247	449,357	2,638,951	(501,119)	(11,034)	12,590	(3,020,215)	246,859
Beginning balance at Mar. 31, 2020	5,108,120	6,373,544	517,741	2,638,951	(501,403)	(40,134)	220,899	(4,323,236)	221,758
Other issuances of common shares and warrants	7,945	35,666	(27,721)
Exercise of warrants	244,990	315,256		(70,266)
Exercise of Omnibus Plan stock options	37,999	61,167	(23,168)
Share-based compensation	69,243		69,243
Issuance and vesting of restricted share units		2,092	(2,092)
Changes in redeemable noncontrolling interest	(41,350)					(51,230)			9,880
Ownership changes relating to noncontrolling interests	5,092				(243)				5,335
Comprehensive (loss) income	(1,247,617)						(193,492)	(1,044,942)	(9,183)
Ending balance at Dec. 31, 2020	$ 4,184,422	$ 6,787,725	$ 534,003	$ 2,568,685	$ (501,646)	$ (91,364)	$ 27,407	$ (5,368,178)	$ 227,790

Condensed Interim Consolidate_5

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,054,125)	$ (61,035)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment	54,625	49,582
Amortization of intangible assets	43,565	26,650
Share of loss on equity method investments	40,851	6,668
Share-based compensation	72,632	241,922
Asset impairment and restructuring costs	459,579
Expected credit losses on financial assets and related charges	108,480
Income tax recovery	(18,086)	(22,948)
Non-cash foreign currency	(11,046)	(3,945)
Interest paid	(12,886)	(13,738)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable	(12,507)	13,749
Prepaid expenses and other assets	(4,353)	(6,214)
Inventory	(28,520)	(240,555)
Accounts payable and accrued liabilities	(8,243)	(11,559)
Other, including non-cash fair value adjustments	2,135	(540,573)
Net cash used in operating activities	(367,899)	(561,996)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment	(137,977)	(610,858)
Purchases of intangible assets	(7,238)	(13,724)
Proceeds on sale of property, plant and equipment	30,921
Proceeds on sale of intangible assets	18,337
(Purchases) redemption of short-term investments	(83,612)	1,324,682
Sale of (investments in) equity method investments	7,000	(4,719)
Investments in other financial assets	(34,236)	(46,647)
Investment in Acreage Arrangement	(49,849)	(395,190)
Loan advanced to Acreage Hempco	(66,995)
Recovery of amounts related to construction financing	10,000
Payment of acquisition related liabilities	(15,144)	(29,837)
Net cash outflow on acquisition of noncontrolling interests	(125)
Net cash outflow on acquisition of subsidiaries		(505,156)
Net cash used in investing activities	(328,918)	(281,449)
Cash flows from financing activities:
Payment of share issue costs	(670)	(245)
Proceeds from issuance of shares by Canopy Rivers	92	1,062
Proceeds from exercise of stock options	37,999	39,149
Proceeds from exercise of warrants	244,990	446
Issuance of long-term debt		10,268
Repayment of long-term debt	(13,271)	(122,036)
Net cash provided by (used in) financing activities	269,140	(71,356)
Effect of exchange rate changes on cash and cash equivalents	(50,539)	(4,365)
Net decrease in cash and cash equivalents	(478,216)	(919,166)
Cash and cash equivalents, beginning of period	1,303,176	2,480,830
Cash and cash equivalents, end of period	824,960	1,561,664
Cash received during the period:
Income taxes	4,176
Cash paid during the period:
Income taxes	20,376	3,220
Noncash investing and financing activities
Additions to property, plant and equipment	$ 16,220	$ 66,402

Description of Business

Description of Business	9 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1 Canopy Growth Corporation is a publicly traded corporation, incorporated in Canada, with its head office located at 1 Hershey Drive, Smiths Falls, Ontario. References herein to “Canopy Growth” or “the Company” refer to Canopy Growth Corporation and its subsidiaries. The principal activities of the Company are the production, distribution and sale of cannabis as regulated by the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) in Canada, up to and including October 16, 2018. On October 17, 2018, the ACMPR was superseded by the Cannabis Act which regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company has also expanded to jurisdictions outside of Canada where cannabis and/or hemp is federally lawful and regulated. The Company and its subsidiaries currently operate in the United States, Europe, Latin America, the Caribbean, and Asia/Pacific. Through its partially owned subsidiary Canopy Rivers Inc. (“Canopy Rivers”), the Company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector, where federally lawful. Refer to Note 19 for a description of the plan of arrangement with Canopy Rivers.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	2 These condensed interim consolidated financial statements have been presented in Canadian dollars and are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Canopy Growth has determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars. Our condensed interim consolidated financial statements, and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated. Certain information and footnote disclosures normally included in the audited annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted or condensed. These condensed interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020 (the “Annual Report”), and have been prepared on a basis consistent with the accounting policies as described in the Annual Report. These condensed interim consolidated financial statements are unaudited and reflect adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods in accordance with U.S. GAAP. The results reported in these condensed interim consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for an entire fiscal year. The policies set out below are consistently applied to all periods presented, unless otherwise noted. Principles of consolidation The accompanying condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Information on the Company’s subsidiaries with noncontrolling interests is included in Note 22. Variable interest entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under Accounting Standards Codification (“ASC”) 810 – Consolidations Equity method investments Investments accounted for using the equity method include those investments where the Company (i) can exercise significant influence over the other entity; and (ii) holds common stock and/or in-substance common stock of the other entity. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company’s share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not reversed in subsequent periods. Refer to Note 10 for additional information on the Company’s investments accounted for using the equity method. Use of estimates The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates. New accounting policies Recently Adopted Accounting Pronouncements Measurement of Credit Losses on Financial Instruments In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Canopy Growth adopted ASU 2016-13 as of April 1, 2020. There was no impact of adopting ASU 2016-13 on the condensed interim consolidated financial statements. Fair Value Measurement In August 2018, the FASB issued ASU 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820) Accounting Guidance not yet adopted Income Taxes In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Investments-Equity Securities In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share (EPS) guidance, and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted after December 15, 2020. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2020-06 effective April 1, 202 2 .

Asset Impairment and Restructur

Asset Impairment and Restructuring Costs	9 Months Ended
	Dec. 31, 2020
Restructuring And Related Activities [Abstract]
Asset Impairment and Restructuring Costs	3. ASSET IMPAIRMENT AND RESTRUCTURING COSTS In the three months ended June 30, 2020, the Company completed certain of the restructuring actions that had commenced in the year ended March 31, 2020, including completing the exit of the Company’s operations in South Africa and Lesotho, and recorded final adjustments related to changes in certain estimates recorded at March 31, 2020. In addition, the Company incurred additional costs in the three months ended June 30, 2020 related primarily to the rationalization of its marketing organization in April 2020. In the three months ended September 30, 2020, the Company recorded (i) adjustments related to changes in the estimated fair value of certain of its Canadian production facilities from March 31, 2020, and (ii) charges related to rationalizing certain research and development activities. In December 2020, as the partial outcome of an ongoing end-to-end strategic review of its operations, the Company announced a series of Canadian operational changes designed to streamline its operations and further improve its gross margins. The Company has ceased operations at its sites in St. John’s, Newfoundland and Labrador; Fredericton, New Brunswick; Edmonton, Alberta; Bowmanville, Ontario; as well as its outdoor cannabis grow operations in Saskatchewan. As a result of these restructuring actions, the Company eliminated approximately 220 full-time positions, and abandoned or impaired certain of its production facilities and intangible assets in the three months ended December 31, 2020. A loss totaling $352,634 was recognized in the three months ended December 31, 2020 representing the difference between the net book value of the long-lived assets and their estimated salvage value or fair value. Of this loss, $298,209 related to property, plant and equipment and $54,425 related to facility licenses and other intangible assets. The losses related to property, plant and equipment were primarily attributable to buildings and greenhouses, production and warehouse equipment, and right-of-use assets. Additionally, the Company recognized contractual and other settlement obligations of $13,058 and employee-related and other restructuring costs of $1,862. Additionally, the Company (i) completed the sale of its production facilities in Aldergrove and Delta, British Columbia in December 2020 and January 2021, respectively, for combined proceeds of $40,650; and (ii) recorded additional charges related to the shifting of the Company’s strategy in Latin America, which the Company commenced in the three months ended March 31, 2020. As a result, a loss totaling $28,437 was recognized in the three months ended December 31, 2020, representing the difference between the net book value of the long-lived assets and their selling price. Additionally, the Company recognized costs totaling $4,431 related to contractual and other settlement obligations, employee-related costs, and other restructuring costs associated with the remediation of damages caused by the fire at the Delta facility in November, the closure of the facilities, and their sale. As a result of the above, in the three and nine months ended December 31, 2020, the Company recognized asset impairment and restructuring costs of $400,422 and $459,579, respectively, in relation to (i) the restructuring actions resulting in the closure of certain of its facilities in Canada in the three months ended December 31, 2020; (ii) adjustments to the net book value of its production facilities in Aldergrove and Delta, British Columbia in order to reflect their selling prices, and other costs associated with their remediation, closure and sale; (iii) charges related to the shifting of the Company’s strategy in Latin America; (iv) completing the exit of the Company’s operations in South Africa and Lesotho; (v) employee-related costs associated with rationalizing certain marketing activities; and (vi) charges related to rationalizing certain research and development activities. Additionally, in the three and nine months ended December 31, 2020, the Company recognized charges of $15,637 in cost of goods sold, primarily relating to inventory write-downs associated with the closure of certain of the Company’s facilities in Canada.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Dec. 31, 2020
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	4. CASH AND CASH EQUIVALENTS The components of cash and cash equivalents are as follows: December 31, March 31, 2020 2020 Cash $ 490,655 $ 679,581 Cash equivalents 334,305 623,595 $ 824,960 $ 1,303,176

Short-term Investments

Short-term Investments	9 Months Ended
	Dec. 31, 2020
Short Term Investments [Abstract]
Short-term Investments	5. SHORT-TERM INVESTMENTS The components of short-term investments are as follows: December 31, March 31, 2020 2020 Term deposits $ 333,265 $ 374,000 Government securities 182,105 226,087 Commercial paper and other 253,194 73,236 $ 768,564 $ 673,323 The amortized cost of short-term investments at December 31, 2020 is $768,859 (March 31, 2020 – $673,022).

Amounts Receivable, Net

Amounts Receivable, Net	9 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Amounts Receivable, Net	6. AMOUNTS RECEIVABLE, NET The components of amounts receivable, net are as follows: December 31, March 31, 2020 2020 Accounts receivable, net $ 74,574 $ 51,166 Interest receivable 6,519 10,303 Indirect taxes receivable 6,242 22,982 Other receivables 6,338 5,704 $ 93,673 $ 90,155 Included in the accounts receivable, net balance at December 31, 2020 is an allowance for doubtful accounts of $815 (March 31, 2020 – $655)

Inventory

Inventory	9 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory	7. INVENTORY The components of inventory are as follows: December 31, March 31, 2020 2020 Raw materials, packaging supplies and consumables $ 69,407 $ 75,507 Work in progress 254,725 255,934 Finished goods 69,891 59,645 $ 394,023 $ 391,086 In the three and nine months ended December 31, 2020, the Company recorded write-downs related to inventory in cost of goods sold of $23,836 and $48,167, respectively, including charges of $15,637 associated with the restructuring actions described in Note 3 (three and nine months ended December 31, 2019 – $6,018 and $32,554, respectively).

Prepaid Expenses and Other Asse

Prepaid Expenses and Other Assets	9 Months Ended
	Dec. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepaid Expenses and Other Assets	8. PREPAID EXPENSES AND OTHER ASSETS The components of prepaid expenses and other assets are as follows: December 31, March 31, 2020 2020 Prepaid expenses $ 38,421 $ 41,423 Deposits 19,904 7,773 Prepaid inventory 1,641 21,217 Other assets 19,013 14,681 $ 78,979 $ 85,094

Pharmhouse

Pharmhouse	9 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Pharmhouse	9. PHARMHOUSE PharmHouse Inc. (“PharmHouse”), a joint venture formed on May 7, 2018, between Canopy Rivers and 2615975 Ontario Limited (the “PharmHouse JV Partner”), is a company licensed to cultivate cannabis under the Cannabis Act. CCAA Proceedings During the nine months ended December 31, 2020, PharmHouse determined that the previously anticipated timeline to generate cash flows from its offtake agreements with the Company and TerrAscend Canada Inc. (“TerrAscend Canada”) would not be met, and the ultimate timing and receipt of cash inflows pursuant to these agreements became uncertain. As a result of this, as well as broader sector-wide challenges impacting the Canadian cannabis industry, PharmHouse did not have sufficient liquidity and capital resources to meet its business objectives and became unable to meet its financial obligations as they became due. Accordingly, on September 15, 2020, PharmHouse obtained an order (the “Initial Order”) from the Ontario Superior Court of Justice (the “Court”) granting PharmHouse creditor protection under the Companies’ Creditors Arrangement Act (“CCAA”) (the “CCAA Proceedings”). The Court appointed an independent professional services firm to act as the Monitor of PharmHouse in the CCAA Proceedings while PharmHouse explores a restructuring of its business and operations (the “Restructuring”). On October 29, 2020, PharmHouse received approval from the Court to commence its Sale and Investor Solicitation Process (“SISP”). The SISP is intended to solicit interest in, and opportunities for, a sale of, or investment in, all or part of PharmHouse’s assets or business. This may include a restructuring, recapitalization, or other form of reorganization of PharmHouse’s business and affairs. Phase one of the SISP concluded on November 30, 2020, and a number of non-binding offers were received. PharmHouse, with the assistance of the Monitor and the SISP advisor, selected a number of parties to bring forward to the next phase of the SISP, and binding offers for phase two of the SISP are due on or about February 16, 2021. PharmHouse Recoverability Assessment As a result of the CCAA Proceedings and the Restructuring, the Company determined that there were indicators of impairment present for its investments in various PharmHouse-related financial assets. These investments are described below. The Company performed impairment testing for its various PharmHouse-related financial assets by estimating the fair value of PharmHouse en bloc. Due to the lack of profitable operating history for PharmHouse as a cannabis entity, the Company estimated the fair value of PharmHouse en bloc using an asset-based approach to value PharmHouse’s assets under an orderly liquidation scenario where cannabis operations are not continued at PharmHouse’s facility and the greenhouse is sold for purposes other than cannabis cultivation. This amount was then compared to the carrying values of the various PharmHouse-related financial instruments held by the Company, in sequence based on the priority of claims on PharmHouse’s assets (the “PharmHouse Recoverability Assessment”). The significant components of this fair value analysis included PharmHouse’s greenhouse facility and retrofits, separable machinery and equipment, saleable inventory, and cash. Significant unobservable inputs used by the Company to determine the fair value of PharmHouse’s assets include the selling price per square foot for PharmHouse’s greenhouse facility; the recoverability percentage on the liquidation of PharmHouse’s property, plant and equipment; the selling price per gram of PharmHouse’s existing cannabis inventory; and adjustments for the risk of fair value changes and liquidity. Based on the foregoing, the Company estimated the recoverable value of PharmHouse’s assets in an orderly liquidation scenario to be approximately $57,500. The impact of the PharmHouse Recoverability Assessment on the Company’s various PharmHouse-related financial instruments is described below. PharmHouse Financial Guarantee Prior to December 31, 2020, PharmHouse had entered into a syndicated credit agreement (as amended, the “PharmHouse Credit Agreement”) with a number of Canadian banks (the “Lenders”) to provide PharmHouse with a committed, non-revolving credit facility (the “PharmHouse Credit Facility”) with a maximum principal amount of $90,000, which was fully drawn. The obligations of PharmHouse under the PharmHouse Credit Facility are secured by guarantees of Canopy Rivers and Canopy Rivers Corporation (“CRC”), a wholly-owned subsidiary of Canopy Rivers, and a pledge by CRC of all of the shares of PharmHouse held by it (the “PharmHouse Financial Guarantee”). Accordingly, if PharmHouse is not able to generate sufficient cash flows to service its obligations pursuant to the PharmHouse Credit Facility, the Company may be required to compensate the Lenders for their loss incurred on the PharmHouse Credit Facility. The PharmHouse Credit Agreement also contains other covenants applicable to Canopy Rivers and CRC. Based on the PharmHouse Recoverability Assessment described above, the Company determined that the fair value of PharmHouse’s assets under an orderly liquidation scenario where the facility is not used for cannabis operations may be less than the principal amount owed by PharmHouse pursuant to the PharmHouse Credit Facility. Accordingly, the Company estimated that it has a financial liability related to the PharmHouse Financial Guarantee, reflecting the estimated shortfall between the recoverable amount of PharmHouse en bloc and the Company’s exposure to the PharmHouse Credit Facility. As at December 31 , 2020, the Company estimated the current expected credit loss related to its contingent obligation under the PharmHouse Financial Guarantee to be $ 32,500 , and recognized a financial liability for this amount in the consolidated balance sheet (March 31, 2020 – $ nil ) (see Note 17) . During the three and nine months ended December 31, 2020, the Company recognized associated current expected credit loss es of $ 7,500 and $ 32,500 in net income (loss) for the three and nine months ended December 31 , 2020 , respectively (three and nine months ended December 31 , 2019 – $ nil ). Other financial assets, including loans receivable As at December 31, 2020, CRC had advanced $40,000 of secured debt financing pursuant to a shareholder loan agreement with PharmHouse (March 31, 2020 – $40,000). The shareholder loan has a three-year As at December 31, 2020, CRC had advanced $2,450 to PharmHouse pursuant to a secured demand promissory note (March 31, 2020 – $2,450). The secured demand promissory note is non-interest bearing both before and after demand or default. Based on the terms of the secured demand promissory note, the Company had recognized the secured demand promissory note as a financial asset initially recorded at fair value and subsequently measured at amortized cost. On August 4, 2020, CRC entered into an unsecured demand promissory note agreement with PharmHouse, pursuant to which it made total advances of $1,206 between August 4, 2020, and September 8, 2020. The unsecured promissory note bears interest at a rate of 12% per annum, calculated and compounded monthly, and is payable on the demand date. Based on the terms of the unsecured demand promissory note, the Company has recognized the instrument as a financial asset initially recorded at fair value and subsequently measured at amortized cost. Pursuant to the Initial Order, CRC entered into an agreement to provide a super-priority, debtor-in-possession (“DIP”) interim, non-revolving credit facility up to a maximum principal amount of $7,214 to PharmHouse (the “DIP Financing”) to enable PharmHouse to continue its day-to-day operations throughout the anticipated Restructuring. The DIP Financing, which is subordinate to PharmHouse’s obligations to the Lenders under the PharmHouse Credit Facility, bears interest at a rate of 8% per annum, calculated and compounded monthly and payable on the maturity date, which is the earlier of December 29, 2020, and the date the CCAA Proceedings are terminated. On December 15, 2020, the DIP Financing agreement entered into between CRC and PharmHouse was amended. As a result of this amendment, the maximum principal amount available to be drawn by PharmHouse pursuant to the DIP Financing increased from $7,214, to $9,700, and the maturity date was extended from December 29, 2020 to February 28, 2021. On December 18, 2020, the Court approved the DIP Financing amendment and extended the stay of proceedings in respect of PharmHouse until February 28, 2021, inclusively. As at December 31, 2020, CRC had advanced $8,300 pursuant to the DIP Financing. As a result of the PharmHouse Recoverability Assessment described above, the Company recognized current expected credit losses of $7,500 and $32,500 for the three and nine months ended December 31, 2020, respectively, related to its contingent obligation under the PharmHouse Financial Guarantee. We also concluded that the following amounts may not be recoverable: (i) $8,300 advanced pursuant to DIP Financing, of which $6,200 was advanced in the three months ended December 31, 2020; (ii) $40,000 advanced under the shareholder loan agreement; (iii) $2,450 advanced under the secured demand promissory note; (iv) $1,206 advanced under the unsecured demand promissory note; and (v) $8,989 in interest receivable in relation to the financial instruments. Additionally, it was determined that certain advances in the amount of $15,000 provided to PharmHouse by the Company may not be recoverable, and costs of $35 were incurred associated with the Restructuring in the three months ended December 31, 2020. Accordingly, the Company recorded expected credit losses on financial assets and related charges of $13,735 and $108,480 for the three and nine months ended December 31, 2020 (three and nine months ended December 31, 2019 - $nil). PharmHouse equity method investment As at December 31, 2020, CRC owned 10,998,660 common shares of PharmHouse (March 31, 2020 – 10,998,660 common shares), representing a 49% equity interest on a non-diluted basis. CRC had not yet received any distributions on account of its common share investment in PharmHouse. As a result of the PharmHouse Recoverability Assessment described above, the Company determined that there was an other-than-temporary-impairment and recognized an impairment charge for the full amount of its equity method investment of $32,369 (see Note 10) in the nine months ended December 31, 2020. Refer to Note 19 for a description of the plan of arrangement with Canopy Rivers.

Equity Method Investments

Equity Method Investments	9 Months Ended
	Dec. 31, 2020
Equity Method Investments And Joint Ventures [Abstract]
Equity Method Investments	10. EQUITY METHOD INVESTMENTS The following table presents changes in the Company’s investments in associates that are accounted for using the equity method in the nine months ended December 31, 2020: Balance at Share of Balance at Ownership March 31, net (loss) Impairment Derecognition December 31, Entity Instrument percentage 2020 income losses of investment 2020 PharmHouse 1 Shares 49% $ 37,025 $ (4,656 ) $ (32,369 ) $ - $ - More Life Shares 40% 10,300 - - - 10,300 CanapaR Shares 49% 8,500 (500 ) - (8,000 ) - Agripharm Shares 40% 5,000 (3,422 ) - - 1,578 Other Shares 18%-27% 5,018 96 - - 5,114 $ 65,843 $ (8,482 ) $ (32,369 ) $ (8,000 ) $ 16,992 1 Where the Company does not have the same reporting date as its investees, the Company will account for its investment one quarter in arrears. Accordingly, certain figures in the above table, including the Company’s share of the investee’s net income (loss), are based on the investees’ results for the nine months ended September 30, 2020 (with respect to December 31, 2020) with adjustments for any signficant transactions. The following tables present current and non-current assets, current and non-current liabilities as well as revenues and net loss of the Company’s equity method investments as at and for the nine months ended September 30, 2020: Current Non-current Current Non-current Entity assets assets liabilities liabilities Revenue Net loss Agripharm $ 5,997 $ 24,273 $ 26,601 $ 1,645 $ 3,310 $ (8,554 ) Other 8,396 20,354 1,729 10,489 5,571 (3,192 ) $ 14,393 $ 44,627 $ 28,330 $ 12,134 $ 8,881 $ (11,746 ) CanapaR On December 30, 2020, CRC sold its share

Other Financial Assets

Other Financial Assets	9 Months Ended
	Dec. 31, 2020
Schedule Of Investments [Abstract]
Other Financial Assets	11. OTHER FINANCIAL ASSETS The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments are calculated are included in Note 23. Foreign Exercise of Balance at currency Allowance options / Balance at March 31, Fair value translation for expected disposal December 31, Entity Instrument 2020 Additions changes adjustments credit losses of shares 2020 TerrAscend Canada Term loan / debenture $ 53,820 $ - $ 10,090 $ - $ - $ - $ 63,910 TerrAscend Exchangeable shares 47,000 - 277,000 - - - 324,000 TerrAscend - March 2020 Warrants 25,004 - 153,446 - - - 178,450 TerrAscend - December 2020 Warrants - 13,720 306 - - - 14,026 Arise Bioscience Term loan - 11,758 446 - - - 12,204 Acreage Hempco 1 Debenture - 66,995 (38,282 ) (2,152 ) - - 26,561 PharmHouse 2 Loan receivable 40,000 - - - (40,000 ) - - ZeaKal Shares 14,186 - (1,486 ) - - - 12,700 Agripharm Royalty interest 12,600 - (7,200 ) - - - 5,400 Greenhouse Convertible debenture 10,517 - (4,117 ) - - (1,300 ) 5,100 Other - at fair value through net income (loss) Various 31,978 10,251 (4,984 ) - - (4,203 ) 33,042 Other - classified as held for investment Loan receivable 14,148 10,106 - - (11,956 ) (5,096 ) 7,202 $ 249,253 $ 112,830 $ 385,219 $ (2,152 ) $ (51,956 ) $ (10,599 ) $ 682,595 1 2 Arise Bioscience On December 10, 2020, the Company entered into a loan financing agreement with Arise Bioscience, Inc. (“Arise Bioscience”), a wholly owned subsidiary of TerrAscend Corp. (“TerrAscend”). The investment is in the amount of US$20,000 ($25,478) (the “Loan”) pursuant to a secured debenture (the “Debenture”). The Debenture bears interest at a rate of 6.1% and is payable beginning in the fourth year after its issuance. The Debenture will mature on December 10, 2030. In connection with the Loan, TerrAscend issued 2,105,718 common share purchase warrants to the Company (the “Warrants”). 1,926,983 Warrants are exercisable at a price of $15.28 per share, and expire on December 10, 2030. 178,735 Warrants are exercisable at a price of $17.19 per share, and expire on December 10, 2031. The Warrants will be exercisable by the Company following changes in U.S. federal laws permitting the cultivation, distribution, and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States. The Loan is repayable by Arise Bioscience at any time. At issuance, the Debenture had a fair value of $11,758 and the Warrants had a fair value of $13,720. As of December 31, 2020, the Debenture had a fair value of $12,204 and the Warrants had a fair value of $14,026. See Note 23 for additional details on how the fair value of the Company’s investment is calculated on a recurring basis.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	12. PROPERTY, PLANT AND EQUIPMENT The components of property, plant and equipment are as follows: December 31, March 31, 2020 2020 Buildings and greenhouses $ 912,435 $ 876,732 Production and warehouse equipment 282,749 300,666 Leasehold improvements 118,456 75,964 Land 43,605 65,003 Office and lab equipment 30,887 29,978 Computer equipment 32,578 30,744 Right-of-use-assets Buildings and greenhouses 116,922 169,754 Production and warehouse equipment 530 927 Assets in process 160,384 365,644 1,698,546 1,915,412 Less: Accumulated depreciation (550,208 ) (390,609 ) $ 1,148,338 $ 1,524,803 Depreciation expense included in cost of goods sold for the three and nine months ended December 31, 2020 is $10,955 and $40,190, respectively (three and nine months ended December 31, 2019 – $13,568 and $35,023, respectively). Depreciation expense included in selling, general and administrative expenses for the three and nine months ended December 31, 2020 is $7,297 and $14,435, respectively (three and nine months ended December 31, 2019 – $6,201 and $14,559, respectively). See Note 3 for information on the impairment and abandonment of property, plant and equipment that the Company recognized in the three months ended December 31, 2020 as part of the restructuring actions resulting in the closure of certain of its facilities in Canada, and adjustments to the net book value of its production facilities in Aldergrove and Delta, British Columbia in order to reflect their selling prices.

Intangible Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2020
Intangible Assets Net Excluding Goodwill [Abstract]
Intangible Assets	13. INTANGIBLE ASSETS The components of intangible assets are as follows: December 31, 2020 March 31, 2020 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Licensed brands $ 67,549 $ 45,265 $ 66,227 $ 53,797 Distribution channel 74,201 38,343 74,768 47,117 Health Canada and operating licenses - - 63,631 57,250 Intellectual property 228,426 186,483 240,386 215,044 Software and domain names 17,940 11,224 16,056 10,013 Amortizable intangibles in process 669 669 9,590 9,590 Total 388,785 281,984 470,658 392,811 Indefinite lived intangible assets Operating licenses $ 8,000 $ 7,000 Acquired brands 76,391 76,555 Total intangible assets $ 366,375 $ 476,366 Amortization expense included in cost of goods sold for the three and nine months ended December 31, 2020 is $99 and $62 , respectively ( three and nine months ended December 31, 2019 , respectively (three and nine months ended December 31, 2019 – $10,624 and $26,541 See Note 3 for information on the impairment and abandonment of intangible assets that the Company recognized in the three months ended December 31, 2020 as part of the restructuring actions resulting in the closure of certain of its facilities in Canada.

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	14. GOODWILL The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2019 $ 1,489,859 Purchase accounting allocations 443,724 Finalization of Storz & Bickel purchase price allocation (24,990 ) Foreign currency translation adjustments 45,878 Balance, March 31, 2020 1,954,471 Foreign currency translation adjustments (36,571 ) Balance, December 31, 2020 $ 1,917,900

Other Accrued Expenses and Liab

Other Accrued Expenses and Liabilities	9 Months Ended
	Dec. 31, 2020
Accounts Payable And Accrued Liabilities Current [Abstract]
Other Accrued Expenses and Liabilities	15. OTHER ACCRUED EXPENSES AND LIABILITIES The components of other accrued expenses and liabilities are as follows: December 31, March 31, 2020 2020 Property, plant and equipment $ 5,059 $ 1,173 Professional fees 11,789 7,677 Employee compensation 33,277 33,415 Other 38,294 22,729 $ 88,419 $ 64,994

Debt

Debt	9 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	16. DEBT The components of debt are as follows: Convertible senior notes December 31, March 31, Maturity Date 2020 2020 Convertible senior notes at 4.25% interest with semi-annual interest payments July 15, 2023 Principal amount $ 600,000 $ 600,000 Accrued interest 12,042 5,454 Non-credit risk fair value adjustment 61,320 (27,120 ) Credit risk fair value adjustment (45,570 ) (128,130 ) 627,792 450,204 Transferred receivables, bearing interest rate of EURIBOR plus 0.850% - 4,678 Other revolving debt facility, loan, and financings 4,404 10,533 632,196 465,415 Less: current portion (13,031 ) (16,393 ) Long-term portion $ 619,165 $ 449,022 On June 20, 2018, the Company issued convertible senior notes (the “notes”) with an aggregate principal amount of $600,000. The notes bear interest at a rate of 4.25% per annum, payable semi-annually on January 15th and July 15th of each year commencing from January 15, 2019. The notes will mature on July 15, 2023. The notes are subordinated in right of payment to any existing and future senior indebtedness, including indebtedness under the revolving credit facility. The notes will rank senior in right of payment to any future subordinated borrowings. The notes are effectively junior to any secured indebtedness and the notes are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries. Holders of the notes may convert the notes at their option at any time from January 15, 2023 to the maturity date. The notes will be convertible, at the holder’s option, at a conversion rate of 20.7577 common shares for every $1 principal amount of notes (equal to an initial conversion price of approximately $48.18 per common share), subject to adjustments in certain events. In addition, the holder has the right to exercise the conversion option from September 30, 2018 to January 15, 2023, if (i) the market price of the Company common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “measurement period”) in which the trading price per $1 principal amount of the notes for each trading day in the measurement period was less than 98% of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the notes are called for redemption or (iv) upon occurrence of certain corporate events (“Fundamental Change”). A Fundamental Change occurred upon completion of the investment by Constellation Brands, Inc. (“CBI”) in the Company in November 2018, and no note holders surrendered any portion of their notes in connection therewith. The Company may, upon conversion by the holder, elect to settle in either cash, common shares, or a combination of cash and common shares, subject to certain circumstances. Under the terms of the indenture, if a Fundamental Change occurs and a holder elects to convert its notes from and including on the date of the Fundamental Change up to, and including, the business day immediately prior to the Fundamental Change repurchase date, the Company may be required to increase the conversion rate for the notes so surrendered for conversion by a number of additional common shares. The Company cannot redeem the notes prior to July 20, 2021, except in the event of certain changes in Canadian tax law. On or after July 20, 2021, the Company could redeem for cash, subject to certain conditions, any or all of the notes, at its option, if the last reported sales price of the Company’s common shares for at least 20 trading days during any 30 consecutive trading day period ending within 5 trading days immediately preceding the date on which the Company provides notice of redemption exceeds 130% of the conversion price on each applicable trading day. The Company may also redeem the notes, if certain tax laws related to Canadian withholding tax change subject to certain further conditions. The redemption of notes in either case shall be at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. For accounting purposes, the equity conversion feature did not meet the equity classification guidance, therefore the Company elected the fair value option under ASC 825 – Financial Instruments credit risk are recorded in other income (expenses), net. The changes in fair value related to the Company’s own credit risk are recorded through other comprehensive income (loss). The overall change in fair value of the notes during the three and nine months ended December 31, 2020, was an increase of $105,588 and $177,588, respectively (three and nine months ended December 31, 2019, a decrease of $47,556 and $292,806, respectively), which included contractual interest of $6,588 and $19,338 (three and nine months ended December 31, 2019, interest of $6,444 and $19,194, respectively). Refer to Note 23 for additional details on how the fair value of the notes is calculated. Transferred receivables The factoring arrangement with PB Factoring GmbH was repaid and subsequently terminated effective December 31, 2020. Other revolving debt facility, loans, and financings On August 13, 2019, the Company, through its wholly owned subsidiary, Tweed Farms Inc., entered into a $40,000 revolving debt facility with Farm Credit Canada (“FCC”). The new facility replaces the previous loans with FCC and is secured by the Company’s property in Niagara-on-the-Lake. The extinguishment of $4,912 in previous FCC debt resulted in no gain or loss. The current outstanding balance of the FCC debt facility is $nil with an interest rate of 3.45%, or FCC prime rate plus 1.0%, and matures on September 3, 2024. The revolving debt facility with FCC is secured by a first charge on the properties in Niagara-on-the-Lake, Ontario, a corporate guarantee from the Company, and a general corporate security agreement .

Other Liabilities

Other Liabilities	9 Months Ended
	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Other Liabilities	17. OTHER LIABILITIES The components of other liabilities are as follows: As at December 31, 2020 As at March 31, 2020 Current Long-term Total Current Long-term Total Acquisition consideration related liabilities $ 33,738 $ 12,323 $ 46,061 $ 104,028 $ 9,791 $ 113,819 Lease liabilities 38,493 98,942 137,435 40,356 120,047 160,403 Minimum royalty obligations 14,942 40,666 55,608 9,368 50,445 59,813 PharmHouse Financial Guarantee 1 32,500 - 32,500 - - - Refund liability 7,140 - 7,140 17,586 - 17,586 Settlement liability 5,206 2,497 7,703 33,162 7,932 41,094 Other 28,287 2,651 30,938 11,309 2,445 13,754 $ 160,306 $ 157,079 $ 317,385 $ 215,809 $ 190,660 $ 406,469 1

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interest	9 Months Ended
	Dec. 31, 2020
Temporary Equity Disclosure [Abstract]
Redeemable Noncontrolling Interest	18. REDEEMABLE NONCONTROLLING INTEREST The net changes in the redeemable noncontrolling interests are as follows: Vert Mirabel BioSteel Total As at March 31, 2020 $ 20,250 $ 49,500 $ 69,750 Net loss attributable to redeemable noncontrolling interest (5,593 ) (4,287 ) (9,880 ) Adjustments to redemption amount 5,543 45,687 51,230 As at December 31, 2020 $ 20,200 $ 90,900 $ 111,100 Vert Mirabel BioSteel Total As at March 31, 2019 $ 6,400 $ - $ 6,400 Initial recognition of noncontrolling interest - 18,733 18,733 Net income (loss) attributable to redeemable noncontrolling interest 4,573 (889 ) 3,684 Adjustments to redemption amount 1,627 7,156 8,783 As at December 31, 2019 $ 12,600 $ 25,000 $ 37,600

Share Capital

Share Capital	9 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Share Capital	19. SHARE CAPITAL CANOPY GROWTH Authorized An unlimited number of common shares. (i) Equity financings There were no equity financings during the nine months ended December 31, 2020 (nine months ended December 31, 2019 - none). (ii) Other issuances of common shares During the nine months ended December 31, 2020, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Completion of acquisition milestones 1,149,086 $ 21,531 $ (13,009 ) Other issuances 412,417 14,135 (14,712 ) Total 1,561,503 $ 35,666 $ (27,721 ) During the nine months ended December 31, 2019, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Acquisition of BC Tweed NCI release from escrow 6,940,531 $ 223,036 $ (223,036 ) Completion of acquisition milestones 610,772 23,055 (23,055 ) Other issuances 621,376 20,371 (20,620 ) Total 8,172,679 $ 266,462 $ (266,711 ) (iii) Warrants Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants (18,876,901 ) 12.98 (70,266 ) Expiry of warrants (343,380 ) 41.49 - Balance outstanding at December 31, 2020 1 127,079,162 $ 58.30 $ 2,568,685 1 Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2019 107,848,322 $ 43.80 $ 1,589,925 Tranche A warrant modification - - 1,049,153 Issuance of Tranche B warrants 38,454,444 76.68 - Other issuance of warrants 9,200 32.83 359 Exercise of warrants (12,523 ) 35.55 (486 ) Balance outstanding at December 31, 2019 1 146,299,443 $ 52.44 $ 2,638,951 1 CANOPY RIVERS Authorized capital Canopy Rivers is authorized to issue an unlimited number of Class A common shares designated as subordinated voting shares (the “Subordinated Voting Shares”) and an unlimited number of Class B common shares designated as multiple voting shares (the “Multiple Voting Shares”). Each Subordinated Voting Share carries the right to one vote per share and each Multiple Voting Share carries the right to 20 votes per share at all meetings of the shareholders of Canopy Rivers. There is no priority or distinction between the two classes of shares in respect of their entitlement to the payment of dividends or participation on liquidation, dissolution or winding-up of Canopy Rivers. Issued and outstanding As at December 31, 2020, Canopy Rivers had 36,468,318 Multiple Voting Shares (March 31, 2020 – 36,468,318) and 155,034,391 Subordinated Voting Shares (March 31, 2020 – 152,837,131) issued and outstanding. As at December 31, 2020, the Company held 36,468,318 Multiple Voting Shares (March 31, 2020 – 36,468,318) and 15,223,938 Subordinated Voting shares (March 31, 2020 – 15,223,938) which represented a 26.9% ownership interest in Canopy Rivers and 84.1% of the voting rights (March 31, 2020 – 27.3% and 84.4% respectively). The voting rights allow the Company to direct the relevant activities of Canopy Rivers such that the Company has control over Canopy Rivers and Canopy Rivers is consolidated in these financial statements. See “Canopy Rivers Arrangement Agreement” below for further details. Financings There were no financings during the nine months ended December 31, 2020, other than the release of shares related to a share purchase financing as noted below. Initial financing 10,066,668 Subordinated Voting Shares were acquired by certain employees of the Company and another individual by way of share purchase loans, whereby funds were advanced to Canopy Rivers by the Company on behalf of such individuals. These Subordinated Voting Shares were initially accounted for as seed capital options and are not considered issued for accounting purposes until the loans are repaid on an individual employee/consultant basis. During the three and nine months ended December 31, 2020, share purchase loans in the amount of $nil and $95, respectively, (three and nine months ended December 31, 2019 – $2 and $50, respectively) relating to Canopy Rivers shares held in trust by the Company on behalf of certain Canopy Growth employees were repaid, resulting in the release from escrow of nil and 1,905,559 Subordinated Voting Shares, respectively (three and nine months ended December 31, 2019 – 38,890 and 999,998, respectively). As at December 31, 2020, there were 33,334 seed capital options outstanding (March 31, 2020 – 2,805,560). Please refer to Note 20 for additional details on the seed capital options. Share buyback On April 2, 2020, Canopy Rivers received approval from the Toronto Stock Exchange (“TSX”) to commence a normal course issuer bid (“NCIB”) to purchase up to 10,409,961 Subordinated Voting Shares, representing 10% of Canopy Rivers’ issued and outstanding Subordinated Voting Shares, in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. The NCIB will expire on April 1, 2021. Daily purchases are limited to 70,653 Subordinating Voting Shares, representing 25% of the average daily trading volume on the TSX over a specified period. The NCIB may be utilized at the sole discretion of Canopy Rivers, with no contractual obligation to purchase any specified number of shares. All Subordinated Voting Share purchases made by Canopy Rivers under the NCIB will be funded out of Canopy Rivers’ working capital and will be cancelled immediately. During the three months ended December 31, 2020, Canopy Rivers repurchased and cancelled a total of nil Subordinated Voting Shares under the NCIB program for $nil, at a weighted average acquisition price of $nil per share (three months ended December 31, 2019 – not applicable). During the nine months ended December 31, 2020, Canopy Rivers repurchased and cancelled a total of 273,300 Subordinated Voting Shares under the NCIB program for $307, at a weighted average acquisition price of $1.11 per share (nine months ended December 31, 2019 – not applicable). Canopy Rivers Arrangement Agreement In December 2020, Canopy Growth entered into an arrangement agreement (the “Canopy Rivers Arrangement Agreement”) with its wholly-owned subsidiary The Tweed Tree Lot Inc. (“Tweed NB”), Canopy Rivers and its wholly-owned subsidiary, CRC, pursuant to which Canopy Growth will acquire certain assets from CRC, as set out below, in exchange for cash, common shares in the capital of Canopy Growth and the surrender of all shares in the capital of Canopy Rivers held by Canopy Growth by way of a plan of arrangement under the Business Corporations Act Pursuant to the Arrangement, Canopy Growth will increase its conditional ownership interest in TerrAscend through the acquisition of (i) 19,445,285 exchangeable shares in the capital of TerrAscend; (ii) 2,225,714 common share purchase warrants in the capital of TerrAscend with an exercise price of $5.95 per share; (iii) 333,723 common share purchase warrants in the capital of TerrAscend with an exercise price of $6.49 per share; and (iv) a $13.2 million loan receivable owing by TerrAscend Canada to CRC. The securities in the capital of TerrAscend are not currently convertible or exercisable, and will not be convertible or exercisable until federal laws in the United States with respect to marijuana are amended. Subject to certain rights of first refusal, pursuant to the Arrangement, Canopy Growth will also acquire all of the common shares and Class A preferred shares in the capital of Les Serres Vert Cannabis Inc. (“Vert Mirabel”) held by CRC. In addition, all of the obligations of Tweed NB owing to CRC pursuant to a royalty agreement between the parties will be terminated. Canopy Growth currently owns 36,468,318 Multiple Voting Shares and 15,223,938 Subordinate Voting Shares in the capital of Canopy Rivers, which represent approximately a 27% ownership interest and 84% of the aggregate voting rights of Canopy Rivers. Pursuant to the Arrangement, all of the Multiple Voting Shares and Subordinate Voting Shares held by Canopy Growth will be repurchased by Canopy Rivers for cancellation on a cashless basis. Canopy Growth will not have any equity, debt or other interest in Canopy Rivers following completion of the Arrangement. As additional consideration for the assets being transferred and the termination of the royalty agreement, Canopy Growth will make a cash payment to CRC of $115.0 million and issue an aggregate of up to 3,750,000 common shares. The Arrangement remains subject to approval by the shareholders of Canopy Rivers at a special shareholder meeting expected to be held on February 16, 2021. The Arrangement does not require the approval of the shareholders of Canopy Growth. In addition to Canopy Rivers shareholder approval, the Arrangement is subject to applicable approvals by the Ontario Superior Court of Justice and certain other closing conditions.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	20. SHARE-BASED COMPENSATION CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLAN Canopy Growth's eligible employees participate in a share-based compensation plan as noted below. On September 21, 2020, the Company’s shareholders approved amendments to the Company’s Amended and Restated Omnibus Incentive Plan (as amended and restated, the “Omnibus Plan”) pursuant to which the Company can issue share-based long-term incentives. The Omnibus Plan approved by the shareholders extended the maximum term of each Option (as defined below) to be granted by the Company to ten years from the date of grant rather than six years from the date of grant. All directors, officers, employees and independent contractors of the Company are eligible to receive awards of common share purchase options (“Options”), restricted share units (“RSUs”), performance share units (“PSUs”), deferred share units, stock appreciation rights, performance awards, or other shares-based awards (collectively, the “Awards”) under the Omnibus Plan. Under the Omnibus Plan, the maximum number of shares issuable from treasury pursuant to Awards shall not exceed 15% of the total outstanding shares from time to time less the number of shares issuable pursuant to all other security-based compensation arrangements of the Company. The maximum number of common shares reserved for Awards is 56,070,568 at December 31, 2020. As of December 31, 2020, the only Awards issued have been Options, RSUs and PSUs under the Omnibus Plan. The Omnibus Plan is administered by the Board of Directors of the Company who establishes exercise prices, at not less than the market price at the date of grant, and expiry dates. Options under the Omnibus Plan generally become exercisable in increments with 1/3 being exercisable on each of the first, second and third anniversaries from the date of grant, with expiry dates set at ten years from issuance. The Board of Directors of the Company has the discretion to amend general vesting provisions and the term of any award, subject to limits contained in the Omnibus Plan. The Employee Share Purchase Plan (the “Purchase Plan”) is the Company’s only other share-based compensation arrangement. Under the Purchase Plan, the aggregate number of common shares that may be issued is 600,000, and the maximum number of common shares which may be issued in any one fiscal year shall not exceed 300,000. As of December 31, 2020, no common shares have been issued under the Purchase Plan. The following is a summary of the changes in the Options outstanding under the Omnibus Plan during the nine months ended December 31, 2020: Options issued Weighted average exercise price Balance outstanding at March 31, 2020 32,508,395 $ 34.89 Options granted 433,199 27.20 Options exercised (3,176,977 ) 11.96 Options forfeited (7,292,634 ) 40.61 Balance outstanding at December 31, 2020 22,471,983 $ 36.12 The following is a summary of the Options as at December 31, 2020: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices December 31, 2020 (years) December 31, 2020 (years) $0.06 - $24.62 3,470,359 3.11 2,173,398 2.12 $24.63 - $33.53 4,669,509 4.28 1,309,942 3.61 $33.54 - $36.80 5,123,061 3.76 3,584,193 3.68 $36.81 - $42.84 4,075,747 4.00 2,542,841 3.74 $42.85 - $67.64 5,133,307 4.15 2,324,913 4.04 22,471,983 3.90 11,935,287 3.47 At December 31, 2020, the weighted average exercise price of Options outstanding and Options exercisable was $36.12 and $35.91, respectively (March 31, 2020 – $34.89 and $31.84, respectively). The Company recorded $16,663 and $54,516 in share-based compensation expense related to Options issued to employees and contractors for the three and nine months ended December 31, 2020, respectively (three and nine months ended December 31, 2019 – $57,735 and $211,053, respectively). The share-based compensation expense for the nine months ended December 31, 2020 includes an amount related to 2,112,745 Options being provided in exchange for services which are subject to performance conditions (for the nine months ended December 31, 2019 – The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2020 and 2019, on their measurement date by applying the following assumptions: December 31, December 31, 2020 2019 Risk-free interest rate 0.49% 1.60% Expected life of options (years) 5 - 7 3 - 5 Expected volatility 73% 73% Expected forfeiture rate 17% 13% Expected dividend yield nil nil Black-Scholes value of each option $23.53 $14.58 Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options. During the nine months ended December 31, 2020, 3,176,977 Options were exercised ranging in price from $0.06 to $36.34 for gross proceeds of $37,999 (for the nine months ended December 31, 2019 – For the three and nine months ended December 31, 2020, the Company recorded $2,685 and $8,870, respectively, in share-based compensation expense (recovery) related to RSUs (for the three and nine months ended December 31, 2019 – $(2,552) and $129, respectively). The following is a summary of the changes in the Company’s RSUs during the nine months ended December 31, 2020: Number of RSUs Balance outstanding at March 31, 2020 883,009 RSUs granted 141,218 RSUs released (75,478 ) RSUs cancelled and forfeited (132,008 ) Balance outstanding at December 31, 2020 816,741 Share-based compensation expense related to acquisition milestones is comprised of: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2020 2019 2020 2019 Canindica $ 604 $ 1,629 $ 1,807 $ 7,925 Spectrum Colombia - 3,365 - 9,765 Other (625 ) (78 ) 4,050 6,621 $ (21 ) $ 4,916 $ 5,857 $ 24,311 During the three and nine months ended December 31, 2020, nil and 1,149,086 common shares, respectively, (during the three and nine months ended December 31, 2019 – 665,297 and 1,232,148, respectively) were released on completion of acquisition milestones. At December 31, 2020, there were up to 3,778,334 common shares to be issued on the completion of acquisition and asset purchase milestones. In certain cases, the number of common shares to be issued is based on the volume weighted average share price at the time the milestones are met. The number of common shares has been estimated assuming the milestones were met at December 31, 2020. The number of common shares excludes common shares that are to be issued on July 4, 2023 to the previous shareholders of Spectrum Colombia S.A.S. (“Spectrum Colombia”) and Canindica Capital Ltd. (“Canindica”) based on the fair market value of the Company’s Latin American business on that date. BioSteel share-based payments On October 1, 2019, the Company purchased 72% of the outstanding shares of BioSteel Sports Nutrition Inc. (“BioSteel”). BioSteel has a stock option plan under which non-transferable options to purchase common shares of BioSteel may be granted to directors, officers, employees, or independent contractors of the BioSteel. As at December 31, 2020, BioSteel had 1,507,000 (March 31, 2020 – 1,008,000) options outstanding which vest in equal tranches over a 5-year period. In determining the amount of share-based compensation related to these options, BioSteel used the Black-Scholes option pricing model to establish the fair value of options on their measurement date. The Company recorded $256 and $918 of share-based compensation expense related to the BioSteel options during the three and nine months ended December 31, 2020, respectively (three and nine months ended December 31, 2019 – $247), with a corresponding increase in noncontrolling interest. CANOPY RIVERS SHARE-BASED COMPENSATION PLAN Seed Capital Options On May 12, 2017, seed capital options were issued. These seed capital options consisted of 10,066,668 shares that were issued by way of share purchase loans. Since they were issued through loans, they are not considered issued for accounting purposes until the loan is repaid. The seed capital options were measured at fair value on May 12, 2017, using a Black-Scholes option pricing model and will be expensed over their vesting period. Where there are performance conditions in addition to service requirements Canopy Rivers has estimated the number of shares it expects to vest and is amortizing the expense over the expected vesting period. Seed capital options issued Seed capital loan balance Balance outstanding at March 31, 2020 2,805,560 $ 140 Options exercised (1,905,559 ) $ (95 ) Options forfeited (533,334 ) $ (26 ) Options expired (333,333 ) $ (17 ) Balance outstanding at December 31, 2020 33,334 $ 2 Canopy Rivers has a long-term incentive plan (“LTIP”) under which non-transferable options, RSUs, PSU, stock appreciation rights, and restricted stock may be granted to directors, officers, employees, or other eligible service providers of Canopy Rivers. Pursuant to the LTIP, the maximum number of Subordinated Voting Shares issuable from treasury pursuant to outstanding options, RSUs and PSUs shall not exceed 10% of the issued and outstanding Subordinated Voting Shares and Multiple Voting Shares, on an aggregate basis. The LTIP is administered by the Board of Directors of Canopy Rivers who establishes exercise prices, at not less than the market price at the date of the grant, and expiry dates. Options under the LTIP generally become exercisable in increments, with one-third being exercisable on each of the first, second, and third anniversaries from the date of grant, and have expiry dates five years from the date of grant. The Board of Directors of Canopy Rivers has the discretion to amend general vesting provisions and the term of any option grant, subject to limits contained in the LTIP. The seed capital options are not within the scope of the LTIP. The following is a summary of the changes in Canopy Rivers’ stock options, excluding the seed capital options presented separately, during the nine months ended December 31, 2020: Options issued Weighted average exercise price Balance outstanding at March 31, 2020 13,066,004 $ 2.31 Options granted - - Options exercised (565,001 ) 0.60 Options expired (492,667 ) 3.62 Options forfeited (621,668 ) 2.64 Balance outstanding at December 31, 2020 11,386,668 $ 2.32 In determining the amount of share-based compensation related to options issued during the year, Canopy Rivers used the Black-Scholes option pricing model to establish the fair value of options granted during the three months ended December 31, 2020 and 2019, on their measurement date by applying the following assumptions: December 31, December 31, 2020 2019 Risk-free interest rate - 1.61% Expected life of options (years) - 3 - 4 Expected volatility - 70% Expected forfeiture rate - nil Expected dividend yield - nil Black-Scholes value of each option - $0.84 Volatility was estimated using companies that Canopy Rivers considers comparable that have trading and volatility history prior to Canopy Rivers becoming public. The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the options. For the three and nine months ended December 31, 2020, the Company recorded $202 and $1,776, respectively, (three and nine months ended December 31, 2019 – $1,333 and $6,182, respectively) in share-based compensation expense related to these options and the seed capital options with a corresponding increase to noncontrolling interests. In the three and nine months ended December 31, 2020, Canopy Rivers granted nil and 28,884 (three and nine months ended December 31, 2019 – none) restricted share units which vest immediately. For the three and nine months ended December 31, 2020, the Company recorded $45 and $157, respectively, (three and nine months ended December 31, 2019 – $nil) of share-based compensation expense related to these restricted share units. In the three and nine months ended December 31, 2020 , Canopy Rivers granted nil and 1,210,000 , respectively ( three and nine months ended December 31, 2019 – none ) performance share units which vest over a three-year period. During the three and nine months ended December 31, 2020, 285,000 performance share units were forfeited (three and nine months ended December 31, 2019 – nil ). For the three and nine months ended December 31, 2020 , the Company recorded $134 and $538 , respectively ( three and nine months ended December 31, 2019 – $nil ) of share-based compensation expense related to these performance share units .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	21. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2020 $ 126,723 $ 94,176 $ 220,899 Other comprehensive loss (110,932 ) (82,560 ) (193,492 ) As at December 31, 2020 $ 15,791 $ 11,616 $ 27,407 Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2019 $ 41,225 $ (47,130 ) $ (5,905 ) Other comprehensive (loss) income (50,995 ) 77,490 26,495 Income tax expense - (8,000 ) (8,000 ) As at December 31, 2019 $ (9,770 ) $ 22,360 $ 12,590

Noncontrolling Interests

Noncontrolling Interests	9 Months Ended
	Dec. 31, 2020
Noncontrolling Interest [Abstract]
Noncontrolling Interests	22. NONCONTROLLING INTERESTS The net change in the noncontrolling interests is as follows: Canopy Rivers Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2020 $ 211,086 $ 7,132 $ 489 $ 3,051 $ 221,758 Comprehensive income (loss) 4,060 (8,956 ) (4,287 ) - (9,183 ) Net loss attributable to redeemable noncontrolling interest - 5,593 4,287 - 9,880 Share-based compensation 2,471 - 918 - 3,389 Ownership changes 1,521 175 - - 1,696 Warrants 250 - - - 250 As at December 31, 2020 $ 219,388 $ 3,944 $ 1,407 $ 3,051 $ 227,790 Canopy Rivers Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2019 $ 280,012 $ 2,422 $ - $ 3,051 $ 285,485 Comprehensive (loss) income (49,005 ) 7,164 (889 ) - (42,730 ) Net income attributable to redeemable noncontrolling interest - (4,573 ) - - (4,573 ) Share-based compensation 6,182 - 247 - 6,429 Ownership changes 1,361 - 887 - 2,248 As at December 31, 2019 $ 238,550 $ 5,013 $ 245 $ 3,051 $ 246,859

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	23. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value measurements are made using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value: • Level 1 – defined as observable inputs such as quoted prices in active markets; • Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value measurement is categorized in its entirety by reference to its lowest level of significant input. The Company records cash, accounts receivable, interest receivable and accounts payable, and other accrued expenses and liabilities at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Assets and liabilities recognized or disclosed at fair value on a nonrecurring basis may include items such as property, plant and equipment, goodwill and other intangible assets, equity and other investments and other assets. We determine the fair value of these items using Level 3 inputs, as described in the related sections below. The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted prices Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2020 Assets: Short-term investments $ 768,564 $ - $ - $ 768,564 Restricted short-term investments 11,426 - - 11,426 Other financial assets 1,392 4,871 669,134 675,397 Liabilities: Convertible senior notes - 627,792 - 627,792 Liability arising from Acreage Arrangement - - 450,000 450,000 Warrant derivative liability - - 415,946 415,946 March 31, 2020 Assets: Short-term investments $ 673,323 $ - $ - $ 673,323 Restricted short-term investments 21,539 - - 21,539 Other financial assets 2,596 36 192,473 195,105 Liabilities: Convertible senior notes - 450,204 - 450,204 Liability arising from Acreage Arrangement - - 250,000 250,000 Warrant derivative liability - - 322,491 322,491 The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Convertible senior note Convertible note pricing model Quoted prices in over-the-counter broker market The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Value and number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend exchangeable shares Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Acreage Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - March 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value TerrAscend Canada term loan Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Arise Bioscience term loan Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - December 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value ZeaKal shares Market approach Share price Increase or decrease in share price will result in an increase or decrease in fair value Greenhouse convertible debenture FinCAD model Share price Increase or decrease in share price will result in an increase or decrease in fair value Agripharm royalty interest and repayable debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future royalties Increase or decrease in future royalties to be paid will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of common share price Increase or decrease in volatility will result in an increase or decrease in fair value Expected life Increase or decrease in expected life will result in an increase or decrease in fair value Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value BioSteel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value Vert Mirabel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value During the nine months ended December 31, 2020 and December 31, 2019, there were no transfers of amounts between levels

Revenue

Revenue	9 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue	24. REVENUE Revenue is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2020 2019 2020 2019 Recreational cannabis revenue Business to business $ 59,106 $ 53,454 $ 157,709 $ 120,556 Business to consumer 20,224 15,242 48,263 38,980 Medical cannabis revenue Canadian 15,349 14,765 45,935 41,965 International 21,505 18,701 59,170 47,287 Other revenue 53,723 33,384 128,746 75,770 Gross revenue 169,907 135,546 439,823 324,558 Excise taxes 17,379 11,782 41,613 33,699 Net revenue $ 152,528 $ 123,764 $ 398,210 $ 290,859 The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $3,750 and $10,900 for the three and nine months ended December 31, 2020, respectively (three and nine months ended December 31, 2019 – $5,343 and $46,070, respectively). As of December 31, 2020, the liability for estimated returns and price adjustments was $7,140 (March 31, 2020 – $17,586).

Other Income (Expense), Net

Other Income (Expense), Net	9 Months Ended
	Dec. 31, 2020
Other Income And Expenses [Abstract]
Other Income (Expense), Net	25. OTHER INCOME (EXPENSE), NET Other income (expense), net is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2020 2019 2020 2019 Fair value changes on other financial assets $ 281,359 $ (77,300 ) $ 385,219 $ (188,122 ) Fair value changes on liability arising from Acreage Arrangement (303,000 ) (30,000 ) (249,849 ) (265,190 ) Fair value changes on convertible senior notes (75,498 ) 6,726 (107,778 ) 202,566 Fair value change on warrant derivative liability (193,998 ) 82,512 (93,455 ) 749,258 Fair value changes on acquisition related contingent consideration (3,066 ) 4,718 39,803 3,078 Interest income 7,310 12,348 19,078 51,529 Interest expense (1,030 ) (2,240 ) (3,708 ) (4,611 ) Foreign currency loss 710 (767 ) (10,290 ) (9,176 ) Gain on acquisition/disposal of consolidated entity - 61,775 - 61,775 Other (expense) income, net (3,354 ) 191 (126 ) (483 ) $ (290,567 ) $ 57,963 $ (21,106 ) $ 600,624

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	26. INCOME TAXES There have been no material changes to income tax matters in connection with normal course operations during the nine months ended December 31, 2020. The Company is subject to income tax in numerous jurisdictions with varying income tax rates. During the most recent period ended and the fiscal year to date, there were no material changes to the statutory income tax rates in the taxing jurisdictions where the majority of the Company’s income for tax purposes was earned, or where its temporary differences or losses are expected to be realized or settled. Although statutory income tax rates remain stable, the Company’s effective income tax rate may fluctuate, arising as a result of the Company’s evolving footprint, discrete transactions and other factors that, to the extent material, are disclosed in these financial statements. The Company continues to believe that the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the reporting period in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company’s estimate, such difference will impact the Company’s income taxes in the reporting period during which such determination is made.

Acreage Arrangement and Amendme

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	9 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants	27. ACREAGE ARRANGEMENT AND AMENDMENTS TO CBI INVESTOR RIGHTS AGREEMENT AND WARRANTS Acreage Arrangement On June 24, 2020, the Company and Acreage Holdings, Inc. (“Acreage”) entered into a proposal agreement to amend the terms of the existing plan of arrangement (the “Prior Arrangement”) made pursuant to an arrangement agreement (the “Acreage Arrangement Agreement”) between the Company and Acreage dated April 18, 2019, as amended on May 15, 2019. Pursuant to the terms of the Prior Arrangement, shareholders of Acreage and holders of certain securities convertible into Existing SVS (as defined below) as of June 26, 2019, received an immediate aggregate total payment of US$300,000 ($395,190) in exchange for granting Canopy Growth both the right and the obligation (the “Acreage financial instrument”) to acquire all of the issued and outstanding shares of Acreage following the occurrence or waiver of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”) and subject to the satisfaction or waiver of the conditions set out in the Acreage Arrangement Agreement. In September 2020, Acreage obtained the requisite approvals of the shareholders of Acreage and the Supreme Court of British Columbia and on September 23, 2020, the Company and Acreage entered into a second amendment to the Acreage Arrangement Agreement and implemented an amended and restated plan of arrangement (the “Amended Arrangement”). The Amended Arrangement provides for, among other things, the following: • A capital reorganization of Acreage (the “Capital Reorganization”), pursuant to which Acreage amended its Notice of Articles and Articles to, among other things, create the Fixed Shares (as defined below), the Floating Shares (as defined below) and the Fixed Multiple Shares (as defined below) and remove the existing Acreage subordinated voting shares (the “Existing SVS”), the existing Acreage proportionate voting shares (the “Existing PVS”) and the existing Acreage multiple voting shares (the “Existing MVS”). Pursuant to the Capital Reorganization (i) each outstanding Existing SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share; (ii) each outstanding Existing PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and (iii) each outstanding Existing MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share; • The new Class E subordinated voting shares (the “Fixed Shares”) have the same attributes as the Existing SVS and are listed on the Canadian Securities Exchange (the “CSE”) under the ticker symbol ACRG.A.U. Following the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event and subject to the satisfaction or waiver of the conditions set out in the Acreage Arrangement Agreement (as modified in connection with the Amended Arrangement), Canopy Growth will acquire all of the issued and outstanding Fixed Shares based on an amended exchange ratio equal to 0.3048 of a common share to be received for each Fixed Share held (reduced from 0.5818 per Existing SVS pursuant to the Prior Arrangement). The foregoing exchange ratio for the Fixed Shares is subject to adjustment in accordance with the Amended Arrangement if, among other things, Acreage issues greater than the permitted number of Fixed Shares; • The new Class D subordinated voting shares (the “Floating Shares”) are listed on the CSE under the ticker symbol ACRG.B.U. Upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event, Canopy Growth will have the right exercisable for a period of 30 days, to acquire all of the issued and outstanding Floating Shares for cash or common shares or a combination thereof, in Canopy Growth’s sole discretion at a price equal to the 30-day volume weighted average trading price of the Floating Shares on the CSE, subject to a minimum call price of US$6.41 per Floating Share. The foregoing exchange ratio for the Floating Shares is subject to adjustment in accordance with the Amended Arrangement if Acreage issues greater than the permitted number of Floating Shares. The acquisition of the Floating Shares, if acquired, will take place concurrently with the closing of the acquisition of the Fixed Shares; • The new Class F multiple voting shares (the “Fixed Multiple Shares”) have the same attributes as the Existing MVS, provided that each Fixed Multiple Share entitles the holder thereof to 4,300 votes per share at shareholder meetings of Acreage. Immediately prior to the acquisition of the Fixed Shares, each issued and outstanding Fixed Multiple Share will automatically be exchanged for one Fixed Share and thereafter be acquired by Canopy Growth upon the same terms and conditions as the acquisition of the Fixed Shares; • If the occurrence or waiver of the Triggering Event does not occur within 10 years from the date the Amended Arrangement was implemented (being September 23, 2030), Canopy Growth’s rights to acquire both the Fixed Shares and the Floating Shares will terminate; • Upon implementation of the Amended Arrangement, Canopy Growth made a cash payment to the shareholders of Acreage and holders of certain securities convertible into Existing SVS in the aggregate amount of US$37,500 ($49,849); and • Acreage is only permitted to issue an aggregate of up to 32,700,000 Fixed Shares and Floating Shares. At December 31, 2020, the Acreage financial instrument represents a financial liability of $450,000 (March 31, 2020 – $250,000), as the estimated fair value of the Acreage business is less than the estimated fair value of the consideration to be provided upon the exercise of the Acreage financial instrument. Fair value changes of $(303,000) and $(249,849) were recognized in other income (expense), net in the three and nine months ended December 31, 2020, respectively (three and nine months ended December 31, 2019 – $(30,000) and $(265,190), respectively) (see Note 25). The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 23 for additional details on how the fair value of the Acreage financial instrument is calculated on a recurring basis. From a measurement perspective, the Company has elected the fair value option under ASC 825. In connection with the Amended Arrangement, on September 23, 2020, an affiliate of the Company advanced US$50,000 ($66,995) to Universal Hemp, LLC, a wholly-owned subsidiary of Acreage (“Acreage Hempco”) pursuant to a secured debenture (“debenture”). In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. The debenture bears interest at a rate of 6.1% per annum, matures 10 years from the implementation of the Amended Arrangement (being September 23, 2030) or such earlier date in accordance with the terms of the debenture, and all interest payments made pursuant to the debenture are payable in cash by Acreage Hempco. The debenture is not convertible and is not guaranteed by Acreage. The amount advanced on September 23, 2020 pursuant to the debenture has been recorded in other financial assets (see Note 11), and the Company has elected the fair value option under ASC 825 (see Note 23). At December 31, 2020, the estimated fair value of the debenture issued to an affiliate of the Company by Acreage Hempco was $26,561, measured using a discounted cash flow model, and fair value changes and foreign currency translation adjustments totaling $(17,120) and $(40,434) were recognized in other income (expense), net in the three and nine months ended December 31, 2020, respectively (see Note 25). An additional US$50,000 may be advanced pursuant to the debenture subject to the satisfaction of certain conditions by Acreage Hempco. Amendment to the CBI Investor Rights Agreement and warrants On April 18, 2019, certain wholly-owned subsidiaries of CBI and Canopy Growth entered into a second amended and restated investor rights agreement and a consent agreement. In connection with these agreements, on June 27, 2019, Canopy Growth (i) extended the term of the first tranche of warrants, which allow CBI to acquire 88.5 million additional shares of Canopy Growth for a fixed price of $50.40 per share (the “Tranche A Warrants”), to November 1, 2023; and (ii) replaced the second tranche of warrants with two new tranches of warrants (the “Tranche B Warrants” and the “Tranche C Warrants”) as follows: • the Tranche B Warrants are exercisable to acquire 38.5 million common shares at a price of C$76.68 per common share; and • the Tranche C Warrants are exercisable to acquire 12.8 million common shares at a price equal to the 5-day volume-weighted average price of the common shares immediately prior to exercise. In connection with the Tranche B Warrants and the Tranche C Warrants, Canopy Growth will provide CBI with a share repurchase credit of up to $1.583 billion on the aggregate exercise price of the Tranche B Warrants and Tranche C Warrants in the event that Canopy Growth does not purchase for cancellation the lesser of (i) 27,378,866 common shares; and (ii) common shares with a value of $1.583 billion, during the period commencing on April 18, 2019 and ending on the date that is 24 months after the date that CBI exercises all of the Tranche A Warrants. The share repurchase credit feature is accounted for as a derivative liability, with the fair value continuing to be $nil at December 31, 2020. The modifications to the Tranche A Warrants resulted in them meeting the definition of a derivative instrument under ASC 815 - Derivatives and Hedging The Tranche B Warrants are accounted for as derivative instruments measured at fair value in accordance with ASC 815. At December 31, 2020, the fair value of the warrant derivative liability was $415,946 (March 31, 2020 – $322,491), and fair value changes of $(193,998) and $(93,455) have been recognized in other income (expense), net in the three and nine months ended December 31, 2020, respectively (three and nine months ended December 31, 2019 – gains of $82,512 and $749,258, respectively) (see Note 25). The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 23 for additional details on how the fair value of the warrant derivative liability is calculated on a recurring basis. The Tranche C Warrants are accounted for as derivative instruments, with the fair value continuing to be $nil at December 31, 2020.

Segment Information

Segment Information	9 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment Information	28. SEGMENT INFORMATION Reportable segments The Company operates in two segments: i) Cannabis, Hemp and Other Consumer Products, which encompasses the production, distribution and sale of a diverse range of cannabis, hemp-based, and other consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits; and ii) Canopy Rivers, a publicly-traded company in Canada, through which the Company provides growth capital and strategic support in the global cannabis sector, where federally lawful. Financial information for Canopy Rivers is included in the table below, and in Note 22. Refer to Note 19 for a description of the plan of arrangement with Canopy Rivers. December 31, 2020 March 31, 2020 Ownership interest 27 % 27 % Cash and cash equivalents $ 37,995 $ 46,724 Prepaid expenses and other current assets 5,839 11,598 Investments in associates 5,113 50,543 Other financial assets 250,532 146,812 Other long-term assets 23,260 22,058 Other liabilities (38,389 ) (2,771 ) Noncontrolling interests (219,388 ) (211,086 ) Equity attributable to Canopy Growth $ 64,962 $ 63,878 Entity-wide disclosures All property, plant and equipment are located in Canada, except for $462,083 which is located outside of Canada as at December 31, 2020 (March 31, 2020 – $499,059). All revenues were principally generated in Canada during the three and nine months ended December 31, 2020, except for $61,468 and $155,126, respectively related to exported medical cannabis and cannabis related merchandise generated outside of Canada (three and nine months ended December 31, 2019 – $43,029 and $100,436, respectively). For the three months ended December 31, 2020, one customer represented more than 10% of the Company’s net revenue (three months ended December 31, 2019 – one). For the nine months ended December 31, 2020, one customer represented more than 10% of the Company’s net revenue (nine months ended December 31, 2019 – one).

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	29. SUBSEQUENT EVENTS TerrAscend Option Agreement On January 13, 2021, the Company entered into an option agreement to acquire 1,072,450 common shares of TerrAscend for US$10,500, conditional upon the occurrence or waiver of amendments to federal laws of the United States to permit the general cultivation, distribution and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The accompanying condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Information on the Company’s subsidiaries with noncontrolling interests is included in Note 22.
Variable interest entities	Variable interest entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under Accounting Standards Codification (“ASC”) 810 – Consolidations
Equity method investments	Equity method investments Investments accounted for using the equity method include those investments where the Company (i) can exercise significant influence over the other entity; and (ii) holds common stock and/or in-substance common stock of the other entity. Under the equity method, investments are carried at cost, and subsequently adjusted for the Company’s share of net income (loss), comprehensive income (loss) and distributions received from the investee. If the current fair value of an investment falls below its carrying amount, this may indicate that an impairment loss should be recorded. Any impairment losses recognized are not reversed in subsequent periods. Refer to Note 10 for additional information on the Company’s investments accounted for using the equity method.
Use of estimates	Use of estimates The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Measurement of Credit Losses on Financial Instruments In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Canopy Growth adopted ASU 2016-13 as of April 1, 2020. There was no impact of adopting ASU 2016-13 on the condensed interim consolidated financial statements. Fair Value Measurement In August 2018, the FASB issued ASU 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820) Accounting Guidance not yet adopted Income Taxes In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Investments-Equity Securities In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) Convertible Instruments and Contracts in an Entity’s Own Equity In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share (EPS) guidance, and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted after December 15, 2020. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2020-06 effective April 1, 202 2 .

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Dec. 31, 2020
Cash And Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	The components of cash and cash equivalents are as follows: December 31, March 31, 2020 2020 Cash $ 490,655 $ 679,581 Cash equivalents 334,305 623,595 $ 824,960 $ 1,303,176

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
	Dec. 31, 2020
Short Term Investments [Abstract]
Components of Short-term Investments	The components of short-term investments are as follows: December 31, March 31, 2020 2020 Term deposits $ 333,265 $ 374,000 Government securities 182,105 226,087 Commercial paper and other 253,194 73,236 $ 768,564 $ 673,323

Amounts Receivable, Net (Tables

Amounts Receivable, Net (Tables)	9 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Components of Amounts Receivable, Net	The components of amounts receivable, net are as follows: December 31, March 31, 2020 2020 Accounts receivable, net $ 74,574 $ 51,166 Interest receivable 6,519 10,303 Indirect taxes receivable 6,242 22,982 Other receivables 6,338 5,704 $ 93,673 $ 90,155

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory are as follows: December 31, March 31, 2020 2020 Raw materials, packaging supplies and consumables $ 69,407 $ 75,507 Work in progress 254,725 255,934 Finished goods 69,891 59,645 $ 394,023 $ 391,086

Prepaid Expenses and Other As_2

Prepaid Expenses and Other Assets (Tables)	9 Months Ended
	Dec. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Components of Prepaid and Other Assets	The components of prepaid expenses and other assets are as follows: December 31, March 31, 2020 2020 Prepaid expenses $ 38,421 $ 41,423 Deposits 19,904 7,773 Prepaid inventory 1,641 21,217 Other assets 19,013 14,681 $ 78,979 $ 85,094

Equity Method Investments (Tabl

Equity Method Investments (Tables)	9 Months Ended
	Dec. 31, 2020
Equity Method Investments And Joint Ventures [Abstract]
Summary of Changes in Investments in Associates that are Accounted for Using Equity Method	The following table presents changes in the Company’s investments in associates that are accounted for using the equity method in the nine months ended December 31, 2020: Balance at Share of Balance at Ownership March 31, net (loss) Impairment Derecognition December 31, Entity Instrument percentage 2020 income losses of investment 2020 PharmHouse 1 Shares 49% $ 37,025 $ (4,656 ) $ (32,369 ) $ - $ - More Life Shares 40% 10,300 - - - 10,300 CanapaR Shares 49% 8,500 (500 ) - (8,000 ) - Agripharm Shares 40% 5,000 (3,422 ) - - 1,578 Other Shares 18%-27% 5,018 96 - - 5,114 $ 65,843 $ (8,482 ) $ (32,369 ) $ (8,000 ) $ 16,992 1
Summary of Financial Information of Equity Method Investments	Where the Company does not have the same reporting date as its investees, the Company will account for its investment one quarter in arrears. Accordingly, certain figures in the above table, including the Company’s share of the investee’s net income (loss), are based on the investees’ results for the nine months ended September 30, 2020 (with respect to December 31, 2020) with adjustments for any signficant transactions. The following tables present current and non-current assets, current and non-current liabilities as well as revenues and net loss of the Company’s equity method investments as at and for the nine months ended September 30, 2020: Current Non-current Current Non-current Entity assets assets liabilities liabilities Revenue Net loss Agripharm $ 5,997 $ 24,273 $ 26,601 $ 1,645 $ 3,310 $ (8,554 ) Other 8,396 20,354 1,729 10,489 5,571 (3,192 ) $ 14,393 $ 44,627 $ 28,330 $ 12,134 $ 8,881 $ (11,746 )

Other Financial Assets (Tables)

Other Financial Assets (Tables)	9 Months Ended
	Dec. 31, 2020
Schedule Of Investments [Abstract]
Summary of Changes in Other Financial Assets	The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments are calculated are included in Note 23. Foreign Exercise of Balance at currency Allowance options / Balance at March 31, Fair value translation for expected disposal December 31, Entity Instrument 2020 Additions changes adjustments credit losses of shares 2020 TerrAscend Canada Term loan / debenture $ 53,820 $ - $ 10,090 $ - $ - $ - $ 63,910 TerrAscend Exchangeable shares 47,000 - 277,000 - - - 324,000 TerrAscend - March 2020 Warrants 25,004 - 153,446 - - - 178,450 TerrAscend - December 2020 Warrants - 13,720 306 - - - 14,026 Arise Bioscience Term loan - 11,758 446 - - - 12,204 Acreage Hempco 1 Debenture - 66,995 (38,282 ) (2,152 ) - - 26,561 PharmHouse 2 Loan receivable 40,000 - - - (40,000 ) - - ZeaKal Shares 14,186 - (1,486 ) - - - 12,700 Agripharm Royalty interest 12,600 - (7,200 ) - - - 5,400 Greenhouse Convertible debenture 10,517 - (4,117 ) - - (1,300 ) 5,100 Other - at fair value through net income (loss) Various 31,978 10,251 (4,984 ) - - (4,203 ) 33,042 Other - classified as held for investment Loan receivable 14,148 10,106 - - (11,956 ) (5,096 ) 7,202 $ 249,253 $ 112,830 $ 385,219 $ (2,152 ) $ (51,956 ) $ (10,599 ) $ 682,595 1 2

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Summary of Expected Useful Life of Property, Plant and Equipment	The components of property, plant and equipment are as follows: December 31, March 31, 2020 2020 Buildings and greenhouses $ 912,435 $ 876,732 Production and warehouse equipment 282,749 300,666 Leasehold improvements 118,456 75,964 Land 43,605 65,003 Office and lab equipment 30,887 29,978 Computer equipment 32,578 30,744 Right-of-use-assets Buildings and greenhouses 116,922 169,754 Production and warehouse equipment 530 927 Assets in process 160,384 365,644 1,698,546 1,915,412 Less: Accumulated depreciation (550,208 ) (390,609 ) $ 1,148,338 $ 1,524,803

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2020
Intangible Assets Net Excluding Goodwill [Abstract]
Summary of Components of Intangible Assets	The components of intangible assets are as follows: December 31, 2020 March 31, 2020 Gross Net Gross Net Carrying Carrying Carrying Carrying Amount Amount Amount Amount Finite lived intangible assets Licensed brands $ 67,549 $ 45,265 $ 66,227 $ 53,797 Distribution channel 74,201 38,343 74,768 47,117 Health Canada and operating licenses - - 63,631 57,250 Intellectual property 228,426 186,483 240,386 215,044 Software and domain names 17,940 11,224 16,056 10,013 Amortizable intangibles in process 669 669 9,590 9,590 Total 388,785 281,984 470,658 392,811 Indefinite lived intangible assets Operating licenses $ 8,000 $ 7,000 Acquired brands 76,391 76,555 Total intangible assets $ 366,375 $ 476,366

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: Balance, March 31, 2019 $ 1,489,859 Purchase accounting allocations 443,724 Finalization of Storz & Bickel purchase price allocation (24,990 ) Foreign currency translation adjustments 45,878 Balance, March 31, 2020 1,954,471 Foreign currency translation adjustments (36,571 ) Balance, December 31, 2020 $ 1,917,900

Other Accrued Expenses and Li_2

Other Accrued Expenses and Liabilities (Tables)	9 Months Ended
	Dec. 31, 2020
Accounts Payable And Accrued Liabilities Current [Abstract]
Components of Other Accrued Expenses and Liabilities	The components of other accrued expenses and liabilities are as follows: December 31, March 31, 2020 2020 Property, plant and equipment $ 5,059 $ 1,173 Professional fees 11,789 7,677 Employee compensation 33,277 33,415 Other 38,294 22,729 $ 88,419 $ 64,994

Debt (Tables)

Debt (Tables)	9 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Summary of Components of Debt	The components of debt are as follows: Convertible senior notes December 31, March 31, Maturity Date 2020 2020 Convertible senior notes at 4.25% interest with semi-annual interest payments July 15, 2023 Principal amount $ 600,000 $ 600,000 Accrued interest 12,042 5,454 Non-credit risk fair value adjustment 61,320 (27,120 ) Credit risk fair value adjustment (45,570 ) (128,130 ) 627,792 450,204 Transferred receivables, bearing interest rate of EURIBOR plus 0.850% - 4,678 Other revolving debt facility, loan, and financings 4,404 10,533 632,196 465,415 Less: current portion (13,031 ) (16,393 ) Long-term portion $ 619,165 $ 449,022

Other Liabilities (Tables)

Other Liabilities (Tables)	9 Months Ended
	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Components of Other Liabilities	The components of other liabilities are as follows: As at December 31, 2020 As at March 31, 2020 Current Long-term Total Current Long-term Total Acquisition consideration related liabilities $ 33,738 $ 12,323 $ 46,061 $ 104,028 $ 9,791 $ 113,819 Lease liabilities 38,493 98,942 137,435 40,356 120,047 160,403 Minimum royalty obligations 14,942 40,666 55,608 9,368 50,445 59,813 PharmHouse Financial Guarantee 1 32,500 - 32,500 - - - Refund liability 7,140 - 7,140 17,586 - 17,586 Settlement liability 5,206 2,497 7,703 33,162 7,932 41,094 Other 28,287 2,651 30,938 11,309 2,445 13,754 $ 160,306 $ 157,079 $ 317,385 $ 215,809 $ 190,660 $ 406,469 1

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interest (Tables)	9 Months Ended
	Dec. 31, 2020
Temporary Equity Disclosure [Abstract]
Summary of Net Change in Redeemable Noncontrolling Interests	The net changes in the redeemable noncontrolling interests are as follows: Vert Mirabel BioSteel Total As at March 31, 2020 $ 20,250 $ 49,500 $ 69,750 Net loss attributable to redeemable noncontrolling interest (5,593 ) (4,287 ) (9,880 ) Adjustments to redemption amount 5,543 45,687 51,230 As at December 31, 2020 $ 20,200 $ 90,900 $ 111,100 Vert Mirabel BioSteel Total As at March 31, 2019 $ 6,400 $ - $ 6,400 Initial recognition of noncontrolling interest - 18,733 18,733 Net income (loss) attributable to redeemable noncontrolling interest 4,573 (889 ) 3,684 Adjustments to redemption amount 1,627 7,156 8,783 As at December 31, 2019 $ 12,600 $ 25,000 $ 37,600

Share Capital (Tables)

Share Capital (Tables)	9 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Summary of Issuances of Stock Other	During the nine months ended December 31, 2020, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Completion of acquisition milestones 1,149,086 $ 21,531 $ (13,009 ) Other issuances 412,417 14,135 (14,712 ) Total 1,561,503 $ 35,666 $ (27,721 ) During the nine months ended December 31, 2019, the Company issued the following shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions: Number of shares Share capital Share based reserve Acquisition of BC Tweed NCI release from escrow 6,940,531 $ 223,036 $ (223,036 ) Completion of acquisition milestones 610,772 23,055 (23,055 ) Other issuances 621,376 20,371 (20,620 ) Total 8,172,679 $ 266,462 $ (266,711 )
Summary of Warrants	Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2020 1 146,299,443 $ 52.44 $ 2,638,951 Exercise of warrants (18,876,901 ) 12.98 (70,266 ) Expiry of warrants (343,380 ) 41.49 - Balance outstanding at December 31, 2020 1 127,079,162 $ 58.30 $ 2,568,685 1 Number of whole warrants Average exercise price Warrant value Balance outstanding at March 31, 2019 107,848,322 $ 43.80 $ 1,589,925 Tranche A warrant modification - - 1,049,153 Issuance of Tranche B warrants 38,454,444 76.68 - Other issuance of warrants 9,200 32.83 359 Exercise of warrants (12,523 ) 35.55 (486 ) Balance outstanding at December 31, 2019 1 146,299,443 $ 52.44 $ 2,638,951 1

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Outstanding Stock Options	The following is a summary of the Options as at December 31, 2020: Options Outstanding Options Exercisable Weighted Average Weighted Average Remaining Remaining Outstanding at Contractual Life Exercisable at Contractual Life Range of Exercise Prices December 31, 2020 (years) December 31, 2020 (years) $0.06 - $24.62 3,470,359 3.11 2,173,398 2.12 $24.63 - $33.53 4,669,509 4.28 1,309,942 3.61 $33.54 - $36.80 5,123,061 3.76 3,584,193 3.68 $36.81 - $42.84 4,075,747 4.00 2,542,841 3.74 $42.85 - $67.64 5,133,307 4.15 2,324,913 4.04 22,471,983 3.90 11,935,287 3.47
Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model	The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 2020 and 2019, on their measurement date by applying the following assumptions: December 31, December 31, 2020 2019 Risk-free interest rate 0.49% 1.60% Expected life of options (years) 5 - 7 3 - 5 Expected volatility 73% 73% Expected forfeiture rate 17% 13% Expected dividend yield nil nil Black-Scholes value of each option $23.53 $14.58
Summary of Changes in RSUs	The following is a summary of the changes in the Company’s RSUs during the nine months ended December 31, 2020: Number of RSUs Balance outstanding at March 31, 2020 883,009 RSUs granted 141,218 RSUs released (75,478 ) RSUs cancelled and forfeited (132,008 ) Balance outstanding at December 31, 2020 816,741
Summary of Share-based Compensation Expense Related to Acquisition Milestones	Share-based compensation expense related to acquisition milestones is comprised of: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2020 2019 2020 2019 Canindica $ 604 $ 1,629 $ 1,807 $ 7,925 Spectrum Colombia - 3,365 - 9,765 Other (625 ) (78 ) 4,050 6,621 $ (21 ) $ 4,916 $ 5,857 $ 24,311
Canopy Rivers Corporation
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model	In determining the amount of share-based compensation related to options issued during the year, Canopy Rivers used the Black-Scholes option pricing model to establish the fair value of options granted during the three months ended December 31, 2020 and 2019, on their measurement date by applying the following assumptions: December 31, December 31, 2020 2019 Risk-free interest rate - 1.61% Expected life of options (years) - 3 - 4 Expected volatility - 70% Expected forfeiture rate - nil Expected dividend yield - nil Black-Scholes value of each option - $0.84
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Changes in Employee Stock Options	The following is a summary of the changes in the Options outstanding under the Omnibus Plan during the nine months ended December 31, 2020: Options issued Weighted average exercise price Balance outstanding at March 31, 2020 32,508,395 $ 34.89 Options granted 433,199 27.20 Options exercised (3,176,977 ) 11.96 Options forfeited (7,292,634 ) 40.61 Balance outstanding at December 31, 2020 22,471,983 $ 36.12
Canopy Rivers Corporation Share Based Compensation Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Changes in Employee Stock Options	The following is a summary of the changes in Canopy Rivers’ stock options, excluding the seed capital options presented separately, during the nine months ended December 31, 2020: Options issued Weighted average exercise price Balance outstanding at March 31, 2020 13,066,004 $ 2.31 Options granted - - Options exercised (565,001 ) 0.60 Options expired (492,667 ) 3.62 Options forfeited (621,668 ) 2.64 Balance outstanding at December 31, 2020 11,386,668 $ 2.32
Canopy Rivers Corporation Share Based Compensation Plan | Seed Capital Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Changes in Employee Stock Options	Seed capital options issued Seed capital loan balance Balance outstanding at March 31, 2020 2,805,560 $ 140 Options exercised (1,905,559 ) $ (95 ) Options forfeited (533,334 ) $ (26 ) Options expired (333,333 ) $ (17 ) Balance outstanding at December 31, 2020 33,334 $ 2

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated other comprehensive income includes the following components: Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2020 $ 126,723 $ 94,176 $ 220,899 Other comprehensive loss (110,932 ) (82,560 ) (193,492 ) As at December 31, 2020 $ 15,791 $ 11,616 $ 27,407 Foreign currency translation adjustments Changes of own credit risk of financial liabilities Accumulated other comprehensive income (loss) As at March 31, 2019 $ 41,225 $ (47,130 ) $ (5,905 ) Other comprehensive (loss) income (50,995 ) 77,490 26,495 Income tax expense - (8,000 ) (8,000 ) As at December 31, 2019 $ (9,770 ) $ 22,360 $ 12,590

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	9 Months Ended
	Dec. 31, 2020
Noncontrolling Interest [Abstract]
Summary of Net Change in Noncontrolling Interests	The net change in the noncontrolling interests is as follows: Canopy Rivers Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2020 $ 211,086 $ 7,132 $ 489 $ 3,051 $ 221,758 Comprehensive income (loss) 4,060 (8,956 ) (4,287 ) - (9,183 ) Net loss attributable to redeemable noncontrolling interest - 5,593 4,287 - 9,880 Share-based compensation 2,471 - 918 - 3,389 Ownership changes 1,521 175 - - 1,696 Warrants 250 - - - 250 As at December 31, 2020 $ 219,388 $ 3,944 $ 1,407 $ 3,051 $ 227,790 Canopy Rivers Vert Mirabel BioSteel Other non- material interests Total As at March 31, 2019 $ 280,012 $ 2,422 $ - $ 3,051 $ 285,485 Comprehensive (loss) income (49,005 ) 7,164 (889 ) - (42,730 ) Net income attributable to redeemable noncontrolling interest - (4,573 ) - - (4,573 ) Share-based compensation 6,182 - 247 - 6,429 Ownership changes 1,361 - 887 - 2,248 As at December 31, 2019 $ 238,550 $ 5,013 $ 245 $ 3,051 $ 246,859

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Dec. 31, 2020
Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis	The following table represents our financial assets and liabilities measured at estimated fair value on a recurring basis: Fair value measurement using Quoted prices Significant prices in other Significant active observable unobservable markets inputs inputs (Level 1) (Level 2) (Level 3) Total December 31, 2020 Assets: Short-term investments $ 768,564 $ - $ - $ 768,564 Restricted short-term investments 11,426 - - 11,426 Other financial assets 1,392 4,871 669,134 675,397 Liabilities: Convertible senior notes - 627,792 - 627,792 Liability arising from Acreage Arrangement - - 450,000 450,000 Warrant derivative liability - - 415,946 415,946 March 31, 2020 Assets: Short-term investments $ 673,323 $ - $ - $ 673,323 Restricted short-term investments 21,539 - - 21,539 Other financial assets 2,596 36 192,473 195,105 Liabilities: Convertible senior notes - 450,204 - 450,204 Liability arising from Acreage Arrangement - - 250,000 250,000 Warrant derivative liability - - 322,491 322,491
Level 2
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments: Financial asset / financial liability Valuation techniques Key inputs Convertible senior note Convertible note pricing model Quoted prices in over-the-counter broker market
Level 3
Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 and Level 3 Financial Instruments	The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments: Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value Acreage financial instrument Probability weighted expected return model Probability of each scenario Change in probability of occurrence in each scenario will result in a change in fair value Value and number of common shares to be issued Increase or decrease in value and number of common shares will result in a decrease or increase in fair value Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Estimated premium on US legalization Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value Control premium Increase or decrease in estimated control premium will result in an increase or decrease in fair value Market access premium Increase or decrease in estimated market access premium will result in an increase or decrease in fair value TerrAscend exchangeable shares Put option pricing model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Acreage Hempco Debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - March 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value TerrAscend Canada term loan Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Arise Bioscience term loan Discounted cash flow Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value TerrAscend warrants - December 2020 Monte Carlo simulation model Probability and timing of US legalization Increase or decrease in probability of US legalization will result in an increase or decrease in fair value ZeaKal shares Market approach Share price Increase or decrease in share price will result in an increase or decrease in fair value Greenhouse convertible debenture FinCAD model Share price Increase or decrease in share price will result in an increase or decrease in fair value Agripharm royalty interest and repayable debenture Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future royalties Increase or decrease in future royalties to be paid will result in an increase or decrease in fair value Warrant derivative liability Monte Carlo simulation model Volatility of common share price Increase or decrease in volatility will result in an increase or decrease in fair value Expected life Increase or decrease in expected life will result in an increase or decrease in fair value Financial asset / financial liability Valuation techniques Significant unobservable inputs Relationship of unobservable inputs to fair value BioSteel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value Vert Mirabel redeemable noncontrolling interest Discounted cash flow Discount rate Increase or decrease in discount rate will result in a decrease or increase in fair value Future wholesale price and production levels Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value During the nine months ended December 31, 2020 and December 31, 2019, there were no transfers of amounts between levels

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenue	Revenue is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2020 2019 2020 2019 Recreational cannabis revenue Business to business $ 59,106 $ 53,454 $ 157,709 $ 120,556 Business to consumer 20,224 15,242 48,263 38,980 Medical cannabis revenue Canadian 15,349 14,765 45,935 41,965 International 21,505 18,701 59,170 47,287 Other revenue 53,723 33,384 128,746 75,770 Gross revenue 169,907 135,546 439,823 324,558 Excise taxes 17,379 11,782 41,613 33,699 Net revenue $ 152,528 $ 123,764 $ 398,210 $ 290,859

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	9 Months Ended
	Dec. 31, 2020
Other Income And Expenses [Abstract]
Schedule of Other Income (Expense), Net	Other income (expense), net is dissaggregated as follows: Three months ended Nine months ended December 31, December 31, December 31, December 31, 2020 2019 2020 2019 Fair value changes on other financial assets $ 281,359 $ (77,300 ) $ 385,219 $ (188,122 ) Fair value changes on liability arising from Acreage Arrangement (303,000 ) (30,000 ) (249,849 ) (265,190 ) Fair value changes on convertible senior notes (75,498 ) 6,726 (107,778 ) 202,566 Fair value change on warrant derivative liability (193,998 ) 82,512 (93,455 ) 749,258 Fair value changes on acquisition related contingent consideration (3,066 ) 4,718 39,803 3,078 Interest income 7,310 12,348 19,078 51,529 Interest expense (1,030 ) (2,240 ) (3,708 ) (4,611 ) Foreign currency loss 710 (767 ) (10,290 ) (9,176 ) Gain on acquisition/disposal of consolidated entity - 61,775 - 61,775 Other (expense) income, net (3,354 ) 191 (126 ) (483 ) $ (290,567 ) $ 57,963 $ (21,106 ) $ 600,624

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Summary of Financial Information for Canopy Rivers	Financial information for Canopy Rivers is included in the table below, and in Note 22. Refer to Note 19 for a description of the plan of arrangement with Canopy Rivers. December 31, 2020 March 31, 2020 Ownership interest 27 % 27 % Cash and cash equivalents $ 37,995 $ 46,724 Prepaid expenses and other current assets 5,839 11,598 Investments in associates 5,113 50,543 Other financial assets 250,532 146,812 Other long-term assets 23,260 22,058 Other liabilities (38,389 ) (2,771 ) Noncontrolling interests (219,388 ) (211,086 ) Equity attributable to Canopy Growth $ 64,962 $ 63,878

Asset Impairment and Restruct_2

Asset Impairment and Restructuring Costs - Additonal Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost And Reserve [Line Items]
Asset impairment and restructuring costs	$ 400,422		$ 459,579
Inventory write-downs	23,836	$ 6,018	48,167	$ 32,554
CANADA
Restructuring Cost And Reserve [Line Items]
Inventory write-downs	15,637		15,637
Aldergrove and Delta [Member]
Restructuring Cost And Reserve [Line Items]
Proceeds from sale of assets	40,650
difference between the net book value of the long-lived assets and their selling price	28,437
recognized costs	4,431		$ 4,431
Operating Expense [Member]
Restructuring Cost And Reserve [Line Items]
Impairment losses	352,634
Operating Expense [Member] | Property Plant And Equipment [Member]
Restructuring Cost And Reserve [Line Items]
Impairment losses	298,209
Operating Expense [Member] | Brand Intellectual Property And License Intangible Assets [Member]
Restructuring Cost And Reserve [Line Items]
Impairment losses	54,425
Operating Expense [Member] | Contractual And Other Settlement Obligations [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	13,058
Operating Expense [Member] | Employee Related And Other Restructuring Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring and other charges	$ 1,862

Cash and Cash Equivalents - Com

Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Cash And Cash Equivalents [Abstract]
Cash	$ 490,655	$ 679,581
Cash equivalents	334,305	623,595
Cash And Cash Equivalents At Carrying Value	$ 824,960	$ 1,303,176

Short-term Investments - Compon

Short-term Investments - Components of Short-term Investments (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Marketable Securities [Line Items]
Short-term investments	$ 768,564	$ 673,323
Term Deposits
Marketable Securities [Line Items]
Short-term investments	333,265	374,000
Government securities
Marketable Securities [Line Items]
Short-term investments	182,105	226,087
Commercial paper and other
Marketable Securities [Line Items]
Short-term investments	$ 253,194	$ 73,236

Short-term Investments - Additi

Short-term Investments - Additional Information (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Short Term Investments [Abstract]
Amortized cost of short-term investments	$ 768,859	$ 673,022

Amounts Receivable, Net - Compo

Amounts Receivable, Net - Components of Amounts Receivable, Net (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Receivables [Abstract]
Accounts receivable, net	$ 74,574	$ 51,166
Interest receivable	6,519	10,303
Indirect taxes receivable	6,242	22,982
Other receivables	6,338	5,704
Amounts receivable, net	$ 93,673	$ 90,155

Amounts Receivable, Net - Addit

Amounts Receivable, Net - Additional Information (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Receivables [Abstract]
Allowance for doubtful accounts	$ 815	$ 655

Inventory - Components of Inven

Inventory - Components of Inventory (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Inventory Disclosure [Abstract]
Raw materials, packaging supplies and consumables	$ 69,407	$ 75,507
Work in progress	254,725	255,934
Finished goods	69,891	59,645
Inventory	$ 394,023	$ 391,086

Inventory - Additional Informat

Inventory - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Inventory [Line Items]
Inventory write-downs	$ 23,836	$ 6,018	$ 48,167	$ 32,554
Inventory write-downs
Inventory [Line Items]
Restructuring and other charges			$ 15,637

Prepaid Expenses and Other As_3

Prepaid Expenses and Other Assets - Components of Prepaid and Other Assets (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 38,421	$ 41,423
Deposits	19,904	7,773
Prepaid inventory	1,641	21,217
Other assets	19,013	14,681
Prepaid and other assets	$ 78,979	$ 85,094

Pharmhouse - Additional informa

Pharmhouse - Additional information (Details) - PharmHouse $ in Thousands	9 Months Ended
	Dec. 31, 2020CAD ($)
Schedule Of Equity Method Investments [Line Items]
Date of formation of joint venture entity	May 7, 2018
Recoverable amount of assets on liquidation	$ 57,500

Pharmhouse - Pharmhouse financi

Pharmhouse - Pharmhouse financial guarantee - Additional information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Line Of Credit Facility [Line Items]
Financial liabilities	$ 2,013,660		$ 2,013,660		$ 1,679,875
Expected credit loss in net income (loss)	(904,380)	$ (91,354)	(1,044,942)	$ (18,305)
Pharmhouse Credit Agreement
Line Of Credit Facility [Line Items]
Non - revolving credit facility, maximum Principle amount	90,000		90,000
Expected credit loss	(32,500)		(32,500)
Expected credit loss in net income (loss)	$ 7,500		$ 32,500

Pharmhouse - Other financial as

Pharmhouse - Other financial assets, including loans receivable - Additional information (Details) - CAD ($) $ in Thousands	Aug. 04, 2020	Dec. 31, 2020	Dec. 31, 2020	Mar. 31, 2020
Schedule Of Equity Method Investments [Line Items]
Debtor-in-possession (“DIP”) interim, non-revolving credit facility up to a maximum principal amount		$ 7,214	$ 7,214
DIP Financing bears interest rate		8.00%	8.00%
Financing increased amount		$ 7,214	$ 7,214
maturity date			Extended from December 29, 2020 to February 28, 2021
Expected credit losses on financial assets and related charges		13,735	$ 108,480
Debtor In Possession
Schedule Of Equity Method Investments [Line Items]
Line of credit facility, pursuant to the agreement		8,300	8,300
Maximum
Schedule Of Equity Method Investments [Line Items]
Financing increased amount		9,700	9,700
PharmHouse
Schedule Of Equity Method Investments [Line Items]
Loss in interest receivable in relation to the financial instruments			8,989
Advances written off		35,000	15,000,000
Expected credit losses on financial assets and related charges		13,735	108,480
PharmHouse | Debtor In Possession
Schedule Of Equity Method Investments [Line Items]
Contingent irrecoverable credit losses		6,200	8,300
PharmHouse | Pharmhouse Credit Agreement
Schedule Of Equity Method Investments [Line Items]
Expected credit losses on financial assets		7,500	32,500
PharmHouse | Shareholder Loan Agreement
Schedule Of Equity Method Investments [Line Items]
Contingent irrecoverable credit losses			40,000
Secured Demand Promissory Note
Schedule Of Equity Method Investments [Line Items]
Secured debt		2,450	2,450	$ 2,450
Secured Demand Promissory Note | PharmHouse
Schedule Of Equity Method Investments [Line Items]
Contingent irrecoverable credit losses			2,450
Unsecured Demand Promissory Note | PharmHouse
Schedule Of Equity Method Investments [Line Items]
Annual interest rate	12.00%
Debt financing pursuant to a unsecured demand promisory note	$ 1,206
Contingent irrecoverable credit losses			1,206
Shareholder Loan Agreement
Schedule Of Equity Method Investments [Line Items]
Secured debt		$ 40,000	$ 40,000	$ 40,000
Debt Instrument Term			3 years
Annual interest rate		12.00%	12.00%
Secured debt payment description			quarterly

Pharmhouse - PharmHouse equity

Pharmhouse - PharmHouse equity method investment - Additional information (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Schedule Of Equity Method Investments [Line Items]
Equity method investments	$ 16,992	$ 65,843
PharmHouse
Schedule Of Equity Method Investments [Line Items]
Common shares owned in joint ventue	10,998,660	10,998,660
Ownership percentage	49.00%
Equity method investments	$ 32,369	$ 37,025

Equity Method Investments - Sum

Equity Method Investments - Summary of Changes in Investments in Associates that are Accounted for Using Equity Method (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2020CAD ($)
Schedule Of Equity Method Investments [Line Items]
Beginning balance	$ 65,843
Share of net loss	(8,482)
Impairment losses	(32,369)
Derocognition of investments	(8,000)
Ending balance	$ 16,992
PharmHouse
Schedule Of Equity Method Investments [Line Items]
Ownership percentage	49.00%
Beginning balance	$ 37,025
Share of net loss	(4,656)
Impairment losses	(32,369)
Ending balance	$ 32,369
More Life
Schedule Of Equity Method Investments [Line Items]
Ownership percentage	40.00%
Beginning balance	$ 10,300
Ending balance	$ 10,300
CanapaR
Schedule Of Equity Method Investments [Line Items]
Ownership percentage	49.00%
Beginning balance	$ 8,500
Share of net loss	(500)
Derocognition of investments	$ (8,000)
Agripharm
Schedule Of Equity Method Investments [Line Items]
Ownership percentage	40.00%
Beginning balance	$ 5,000
Share of net loss	(3,422)
Ending balance	1,578
Other
Schedule Of Equity Method Investments [Line Items]
Beginning balance	5,018
Share of net loss	96
Ending balance	$ 5,114
Other | Minimum [Member]
Schedule Of Equity Method Investments [Line Items]
Ownership percentage	18.00%
Other | Maximum
Schedule Of Equity Method Investments [Line Items]
Ownership percentage	27.00%

Equity Method Investments - S_2

Equity Method Investments - Summary of Financial Information of Equity Method Investments (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Schedule Of Equity Method Investments [Line Items]
Current assets	$ 2,171,625		$ 2,171,625		$ 2,564,373
Current liabilities	348,219		348,219		$ 420,589
Net loss	(829,251)	$ (109,634)	(1,054,125)	$ (61,035)
Equity Method Investment, Nonconsolidated Investee
Schedule Of Equity Method Investments [Line Items]
Current assets	14,393		14,393
Non-current assets	44,627		44,627
Current liabilities	28,330		28,330
Non-current liabilities	12,134		12,134
Revenue			8,881
Net loss			(11,746)
Equity Method Investment, Nonconsolidated Investee | Agripharm
Schedule Of Equity Method Investments [Line Items]
Current assets	5,997		5,997
Non-current assets	24,273		24,273
Current liabilities	26,601		26,601
Non-current liabilities	1,645		1,645
Revenue			3,310
Net loss			(8,554)
Equity Method Investment, Nonconsolidated Investee | Other
Schedule Of Equity Method Investments [Line Items]
Current assets	8,396		8,396
Non-current assets	20,354		20,354
Current liabilities	1,729		1,729
Non-current liabilities	$ 10,489		10,489
Revenue			5,571
Net loss			$ (3,192)

Equity Method investments - Add

Equity Method investments - Additional information (Details) - CanapaR	9 Months Ended
	Dec. 31, 2020USD ($)
Schedule Of Equity Method Investments [Line Items]
Contingent consideration for shares sold	$ 1,000
Cash	$ 7,000

Other Financial Assets - Summar

Other Financial Assets - Summary of Changes in Other Financial Assets (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2020CAD ($)
Schedule Of Investments [Line Items]
Beginning balance	$ 249,253
Additions	112,830
Fair value changes	385,219
Foreign currency translation adjustments	(2,152)
Allowance For Expected Credit loss	(51,956)
Exercise of options / disposal of shares	(10,599)
Ending balance	682,595
TerrAscend | Exchangeable Shares
Schedule Of Investments [Line Items]
Beginning balance	47,000
Fair value changes	277,000
Ending balance	324,000
TerrAscend - March 2020 | Warrants
Schedule Of Investments [Line Items]
Beginning balance	25,004
Fair value changes	153,446
Ending balance	178,450
TerrAscend Canada | Term loan / debenture
Schedule Of Investments [Line Items]
Beginning balance	53,820
Fair value changes	10,090
Ending balance	63,910
TerrAscend - December 2020 | Warrants
Schedule Of Investments [Line Items]
Additions	13,720
Fair value changes	306
Ending balance	14,026
Acreage Hempco1 | Debenture
Schedule Of Investments [Line Items]
Additions	66,995	[1]
Fair value changes	(38,282)	[1]
Foreign currency translation adjustments	(2,152)	[1]
Ending balance	26,561	[1]
PharmHouse | Loan Receivable
Schedule Of Investments [Line Items]
Beginning balance	40,000	[2]
Allowance For Expected Credit loss	(40,000)	[2]
Arise Bioscience | Term Loan
Schedule Of Investments [Line Items]
Additions	11,758
Fair value changes	446
Ending balance	12,204
Agripharm | Royalty Interest
Schedule Of Investments [Line Items]
Beginning balance	12,600
Fair value changes	(7,200)
Ending balance	5,400
ZeaKal | Shares
Schedule Of Investments [Line Items]
Beginning balance	14,186
Fair value changes	(1,486)
Ending balance	12,700
Greenhouse | Convertible Debenture
Schedule Of Investments [Line Items]
Beginning balance	10,517
Fair value changes	(4,117)
Exercise of options / disposal of shares	(1,300)
Ending balance	5,100
Other At Fair Value Through Net Income Loss | Various
Schedule Of Investments [Line Items]
Beginning balance	31,978
Additions	10,251
Fair value changes	(4,984)
Exercise of options / disposal of shares	(4,203)
Ending balance	33,042
Other - Classified as Held for Investment | Loan Receivable
Schedule Of Investments [Line Items]
Beginning balance	14,148
Additions	10,106
Allowance For Expected Credit loss	(11,956)
Exercise of options / disposal of shares	(5,096)
Ending balance	$ 7,202
[1]	See Note 27 for information regarding Acreage Hempco
[2]	See Note 9 for information regarding PharmHouse.

Other Financial Assets - Additi

Other Financial Assets - Additional Information (Details) - Arise Bioscience $ / shares in Units, $ in Thousands, $ in Thousands	Dec. 10, 2020CAD ($)$ / sharesshares	Dec. 31, 2020CAD ($)	Dec. 10, 2020USD ($)
First Tranche
Schedule Of Investments [Line Items]
Warrants exercisable	1,926,983
Warrant exercisable price per share | $ / shares	$ 15.28
Warrants exercisable expiration date	Dec. 10, 2030
Second Tranche
Schedule Of Investments [Line Items]
Warrants exercisable	178,735
Warrant exercisable price per share | $ / shares	$ 17.19
Warrants exercisable expiration date	Dec. 10, 2031
Warrant
Schedule Of Investments [Line Items]
Investment in subsidiary | $	$ 13,720	$ 14,026
Sale of Stock, Number of Shares Issued in Transaction	2,105,718
Debenture
Schedule Of Investments [Line Items]
Investment in subsidiary | $	$ 11,758	$ 12,204
Debenture | Loan
Schedule Of Investments [Line Items]
Investment in subsidiary	$ 25,478		$ 20,000
Debenture maturity date	Dec. 10, 2030
Annual interest rate	6.10%		6.10%

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Components of Property, Plant and Equipment (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,698,546	$ 1,915,412
Less: Accumulated depreciation	(550,208)	(390,609)
Property, plant and equipment, net	1,148,338	1,524,803
Buildings and Greenhouses
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	912,435	876,732
Buildings and Greenhouses | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	116,922	169,754
Production and Warehouse Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	282,749	300,666
Production and Warehouse Equipment | Right-of-Use-Assets
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	530	927
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	118,456	75,964
Land
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	43,605	65,003
Office and Lab Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	30,887	29,978
Computer Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	32,578	30,744
Assets in Process
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 160,384	$ 365,644

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment			$ 54,625	$ 49,582
Cost of Goods Sold
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 10,955	$ 13,568	40,190	35,023
Selling, General and Administrative Expenses
Property Plant And Equipment [Line Items]
Depreciation of property, plant and equipment	$ 7,297	$ 6,201	$ 14,435	$ 14,559

Intangible Assets - Summary of

Intangible Assets - Summary of Components of Intangible Assets (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	$ 388,785	$ 470,658
Net Carrying Amount	281,984	392,811
Total intangible assets	366,375	476,366
Licensed Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	67,549	66,227
Net Carrying Amount	45,265	53,797
Distribution Channel
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	74,201	74,768
Net Carrying Amount	38,343	47,117
Health Canada and Operating Licenses
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	0	63,631
Net Carrying Amount	0	57,250
Intellectual Property
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	228,426	240,386
Net Carrying Amount	186,483	215,044
Software and Domain Names
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	17,940	16,056
Net Carrying Amount	11,224	10,013
Amortizable Intangibles in Process
Intangible Assets Net Excluding Goodwill [Line Items]
Gross Carrying Amount	669	9,590
Net Carrying Amount	669	9,590
Operating Licenses
Intangible Assets Net Excluding Goodwill [Line Items]
Indefinite lived intangible assets	8,000	7,000
Acquired Brands
Intangible Assets Net Excluding Goodwill [Line Items]
Indefinite lived intangible assets	$ 76,391	$ 76,555

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets			$ 43,565	$ 26,650
Cost of Goods Sold
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 62	$ 71	99	109
Selling, General and Administrative Expenses
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 14,034	$ 10,624	$ 43,503	$ 26,541

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Details) - CAD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 1,954,471	$ 1,489,859
Purchase accounting allocations		443,724
Finalization of Storz & Bickel purchase price allocation		(24,990)
Foreign currency translation adjustments	(36,571)	45,878
Ending Balance	$ 1,917,900	$ 1,954,471

Other Accrued Expenses and Li_3

Other Accrued Expenses and Liabilities - Components of Other Accrued Expenses and Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Accounts Payable And Accrued Liabilities Current [Abstract]
Property, plant and equipment	$ 5,059	$ 1,173
Professional fees	11,789	7,677
Employee compensation	33,277	33,415
Other	38,294	22,729
Other accrued expenses and liabilities	$ 88,419	$ 64,994

Debt - Summary of Components of

Debt - Summary of Components of Debt (Details) - CAD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2020
Debt Instrument [Line Items]
Other revolving debt facility, loan, and financings	$ 4,404	$ 10,533
Long Term Debt	632,196	465,415
Less: current portion	(13,031)	(16,393)
Long-term portion	$ 619,165	449,022
Euribor [Member]
Debt Instrument [Line Items]
Transferred receivables, bearing interest rate of EURIBOR plus 0.850%		4,678
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debenture maturity date	Jul. 15, 2023
Principal amount	$ 600,000	600,000
Accrued interest	12,042	5,454
Non-credit risk fair value adjustment	61,320	(27,120)
Credit risk fair value adjustment	(45,570)	(128,130)
Senior Notes	$ 627,792	$ 450,204

Debt - Summary of Components _2

Debt - Summary of Components of Debt (Parenthetical) (Details)	9 Months Ended
	Dec. 31, 2020
Euribor [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.85%
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Annual interest rate	4.25%

Debt - Additional Information (

Debt - Additional Information (Details)	Aug. 13, 2019CAD ($)	Jun. 20, 2018CAD ($)Trading_Day$ / shares	Dec. 31, 2020CAD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2020CAD ($)	Dec. 31, 2019CAD ($)
Tweed Farms Inc | Farm Credit Canada | Revolving Credit Facility
Debt Instrument [Line Items]
Interest at a rate			3.45%		3.45%
Maturity date					Sep. 3, 2024
Non - revolving credit facility, maximum Principle amount	$ 40,000,000
Extinguishment of debt, amount	$ 4,912,000
Debt instrument, description of variable rate basis					prime rate plus 1.0%
Debt Instrument, Basis Spread on Variable Rate					1.00%
4.25% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal amount		$ 600,000,000
Interest at a rate		4.25%
Frequency of periodic payment team		semi-annually on January 15th and July 15th of each year commencing from January 15, 2019
Maturity date		Jul. 15, 2023
Convertible senior notes conversion time start from		Jan. 15, 2023
Conversion rate for every dollar one of principal amount of notes | $ / shares		$ 20.7577
Convertible, If-converted value in excess of principal		$ 1,000
Conversion price | $ / shares		$ 48.18
Debt Conversion, Description		(i) the market price of the Company common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “measurement period”) in which the trading price per $1 principal amount of the notes for each trading day in the measurement period was less than 98% of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the notes are called for redemption or (iv) upon occurrence of certain corporate events (“Fundamental Change”). A Fundamental Change occurred upon completion of the investment by Constellation Brands, Inc. (“CBI”) in the Company in November 2018, and no note holders surrendered any portion of their notes in connection therewith
Conversion price percentage		130.00%			130.00%
Convertible measurement period threshold trading days		5 days
Convertible measurement period threshold consecutive trading days		5 days
Convertible conversion price | $ / shares		$ 1
Maximum discount to last reported sales price		98.00%
Debt instrument, redemption, description					The Company cannot redeem the notes prior to July 20, 2021, except in the event of certain changes in Canadian tax law.
Debt instrument, redemption period, start date					Jul. 20, 2021
Debt instrument, redemption threshold trading days					20 days
Debt instrument, redemption threshold consecutive trading days					30 days
Number of trading days to provide notice of redemption					5 days
Debt instrument, redemption price, percentage					100.00%
Debt instrument, change in fair value of notes			$ 105,588,000	$ 47,556,000	$ 177,588,000	$ 292,806,000
Debt instrument, change in fair value of notes from contractual interest			$ 6,588,000	$ 6,444,000	$ 19,338,000	$ 19,194,000
4.25% Convertible Senior Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Threshold consecutive trading days | Trading_Day		20
4.25% Convertible Senior Notes [Member] | Maximum
Debt Instrument [Line Items]
Threshold consecutive trading days | Trading_Day		30

Other Liabilities - Components

Other Liabilities - Components of Other Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Current
Acquisition consideration related liabilities, current	$ 33,738	$ 104,028
Lease liabilities, current	38,493	40,356
Minimum royalty obligations, current	14,942	9,368
Refund liability, current	7,140	17,586
Settlement liability, current	5,206	33,162
Other, current	28,287	11,309
Other liabilities, current	160,306	215,809
Long-term
Acquisition consideration related liabilities, long-term	12,323	9,791
Lease liabilities, long-term	98,942	120,047
Minimum royalty obligations, long-term	40,666	50,445
Settlement liability, long-term	2,497	7,932
Other, long-term	2,651	2,445
Other liabilities, long-term	157,079	190,660
Total
Acquisition consideration related liabilities	46,061	113,819
Lease liabilities	137,435	160,403
Minimum royalty obligations	55,608	59,813
Refund liability	7,140	17,586
Settlement liability	7,703	41,094
Other	30,938	13,754
Other liabilities	317,385	$ 406,469
Pharmhouse Credit Agreement
Current
PharmHouse Financial Guarantee, Current	32,500
Total
PharmHouse Financial Guarantee	$ 32,500

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interest - Summary of Net Change in Redeemable Noncontrolling Interests (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	$ 69,750	$ 6,400
Initial recognition of noncontrolling interest		18,733
Net income (loss) attributable to redeemable noncontrolling interest	(9,880)	3,684
Adjustments to redemption amount	51,230	8,783
Ending balance	111,100	37,600
Vert Mirabel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	20,250	6,400
Net income (loss) attributable to redeemable noncontrolling interest	(5,593)	4,573
Adjustments to redemption amount	5,543	1,627
Ending balance	20,200	12,600
Bio Steel
Redeemable Noncontrolling Interest [Line Items]
Beginning balance	49,500
Initial recognition of noncontrolling interest		18,733
Net income (loss) attributable to redeemable noncontrolling interest	(4,287)	(889)
Adjustments to redemption amount	45,687	7,156
Ending balance	$ 90,900	$ 25,000

Share Capital - Additional Info

Share Capital - Additional Information (Details)	Apr. 02, 2020shares	Dec. 31, 2020CAD ($)$ / sharesshares	Dec. 31, 2020CAD ($)$ / sharesshares	Dec. 31, 2019CAD ($)shares	Dec. 31, 2020CAD ($)$ / sharesshares	Dec. 31, 2019CAD ($)shares	Mar. 31, 2020shares
Class Of Stock [Line Items]
Number of equity financings		0	0	0	0	0
Financings other than release of shares related to share purchase financing | $					$ 0
Business consideration transferred | $					$ 115,000,000
Business consideration transferred, share issued					3,750,000
Arrangement | Tweed N B
Class Of Stock [Line Items]
Shares issued		19,445,285	19,445,285		19,445,285
Arrangement | Tweed N B | Term Loan
Class Of Stock [Line Items]
Investment in subsidiary | $		$ 13,200,000	$ 13,200,000		$ 13,200,000
Arrangement | Tweed N B | First Tranche
Class Of Stock [Line Items]
common share purchase warrants in the capital		2,225,714
Warrant price per share | $ / shares		$ 5.95	$ 5.95		$ 5.95
Arrangement | Tweed N B | Second Tranche
Class Of Stock [Line Items]
common share purchase warrants in the capital		333,723
Warrant price per share | $ / shares		$ 6.49	$ 6.49		$ 6.49
Subordinated Voting Shares
Class Of Stock [Line Items]
Daily purchases of common shares, limit	70,653
Average daily trading volume	25.00%
Canopy Rivers
Class Of Stock [Line Items]
Common Stock, Voting Rights					Each Subordinated Voting Share carries the right to one vote per share and each Multiple Voting Share carries the right to 20 votes per share at all meetings of the shareholders of Canopy Rivers.
Ownership percentage		26.90%	26.90%		26.90%		27.30%
Voting rights percentage		84.10%	84.10%		84.10%		84.40%
Share purchase loan amount repaid | $				$ 2,000	$ 95,000	$ 50,000
Seed capital options outstanding		33,334	33,334		33,334		2,805,560
Ownership interest percentage		27.00%	27.00%		27.00%
Voting rights percentage		84.00%	84.00%		84.00%
Canopy Rivers | Multiple Voting Shares
Class Of Stock [Line Items]
Shares issued		36,468,318	36,468,318		36,468,318		36,468,318
Shares outstanding		36,468,318	36,468,318		36,468,318		36,468,318
Treasury shares		36,468,318	36,468,318		36,468,318		36,468,318
Shares issued					36,468,318
Canopy Rivers | Subordinated Voting Shares
Class Of Stock [Line Items]
Shares issued		155,034,391	155,034,391		155,034,391		152,837,131
Shares outstanding		155,034,391	155,034,391		155,034,391		152,837,131
Treasury shares		15,223,938	15,223,938		15,223,938		15,223,938
Shares acquired by way of share purchase loans			10,066,668
Number of shares released from escrow				38,890	1,905,559	999,998
Maximum number of shares authorized to be repurchased	10,409,961
Percentage of subordinated voting shares issuable from treasury	10.00%
NCIB expiration date	Apr. 1, 2021
Stock repurchased and cancelled, shares					273,300
Stock Repurchased And Cancelled Value | $					$ 307,000
Weighted Average price, per share | $ / shares					$ 1.11
Shares issued					15,223,938

Share Capital - Summary of Issu

Share Capital - Summary of Issuances of Stock Other (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Equity Class Of Treasury Stock [Line Items]
Number of shares	1,561,503	8,172,679
Completion of acquisition milestones, Number of shares	1,149,086	610,772
Share capital	$ 35,666	$ 266,462
Share based reserve	(27,721)	(266,711)
Share Capital
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	21,531	23,055
Share-based Reserve
Equity Class Of Treasury Stock [Line Items]
Completion of acquisition milestones	$ (13,009)	$ (23,055)
Other Issuances
Equity Class Of Treasury Stock [Line Items]
Number of shares	412,417	621,376
Share capital	$ 14,135	$ 20,371
Share based reserve	$ (14,712)	$ (20,620)
BC Tweed NCI
Equity Class Of Treasury Stock [Line Items]
Number of shares		6,940,531
Share capital		$ 223,036
Share based reserve		$ (223,036)

Share Capital - Summary of Warr

Share Capital - Summary of Warrants (Details) - CAD ($)	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class Of Warrant Or Right [Line Items]
Number of whole warrants, Beginning balance	146,299,443	107,848,322
Number of whole warrants, Other issuance of warrants		9,200
Number of whole warrants, Exercise of warrants	(18,876,901)	(12,523)
Number of whole warrants, Expiry of warrants	(343,380)
Number of whole warrants, Ending balance	127,079,162	146,299,443
Average exercise price, Beginning balance	$ 52.44	$ 43.80
Average exercise price, Other issuance of warrants		$ 32.83
Average exercise price, Exercise of warrants	12.98	$ 35.55
Average exercise price, Expiry of warrants	41.49
Average exercise price, Ending balance	$ 58.30	$ 52.44
Warrant value, Beginning balance	$ 2,638,951,000	$ 1,589,925,000
Warrant value, Other issuance of warrants		359
Warrant value, Exercise of warrants	(70,266,000)	(486,000)
Warrant value, Expiry of warrants
Warrant value, Ending balance	$ 2,568,685,000	2,638,951,000
Tranche A
Class Of Warrant Or Right [Line Items]
Warrant value, Warrant modification		$ 1,049,153,000
Tranche B
Class Of Warrant Or Right [Line Items]
Number of whole warrants, Issuance of warrants		38,454,444
Average exercise price, Issuance of warrants		$ 76.68

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - CAD ($) $ / shares in Units, $ in Thousands	Sep. 21, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Oct. 01, 2019	May 12, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options extended period	10 years
Options maximum period	6 years
Weighted average exercise price of options outstanding		$ 36.12		$ 36.12		$ 34.89
Weighted average exercise price of options exercisable		$ 35.91		$ 35.91		$ 31.84
Share-based compensation expense		$ (21)	$ 4,916	$ 5,857	$ 24,311
Proceeds from exercise of stock options				$ 37,999	$ 39,149
Number of common shares released on completion of acquisition milestones			665,297	1,149,086	1,232,148
Number of shares to be issued on completion of acquisition and asset purchase milestones				3,778,334
Stock options outstanding		22,471,983		22,471,983
Share-based compensation		$ 19,963	$ 61,679	$ 72,632	$ 241,922
Canopy Rivers Corporation
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense		$ 202	1,333	$ 1,776	6,182
Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Seed capital options issued								10,066,668
Bio Steel Sports Nutrition Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Voting rights percentage							72.00%
Stock options outstanding		1,507,000		1,507,000		1,008,000
Vesting period				5 years
Share-based compensation		$ 256	247	$ 918	247
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense		16,663	57,735	$ 54,516	$ 211,053
Stock Option Subject To Performance Conditions
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense, options subject to performance conditions				2,112,745	445,000
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense		2,685	$ (2,552)	$ 8,870	$ 129
PSUs forfeited				132,008
RSUs | Canopy Rivers Corporation
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense		45		$ 157
Value of RSUs granted		28,884		28,884
PSUs | Canopy Rivers Corporation
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense		134		$ 538
Vesting period				3 years
Value of RSUs granted		$ 1,210,000		$ 1,210,000
PSUs forfeited		285,000		285,000
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares reserved for Awards		56,070,568		56,070,568
Options expiration period	10 years
Weighted average exercise price of options outstanding		$ 36.12		$ 36.12		$ 34.89
Options exercised				3,176,977	3,642,733
Exercise price				$ 11.96
Proceeds from exercise of stock options				$ 37,999	$ 39,149
Stock options outstanding		22,471,983		22,471,983		32,508,395
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant	33.33%
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant	33.33%
Omnibus Incentive Plan | Share-based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant	33.33%
Omnibus Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares issuable from treasury pursuant to awards	15.00%
Exercise price				$ 36.34	$ 40.68
Omnibus Incentive Plan | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price				$ 0.06	$ 0.22
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of common shares authorized	600,000
Equity shares issued to shareholders				0
Employee Stock Purchase Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity shares issued to shareholders	300,000
Canopy Rivers Corporation Share Based Compensation Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options expiration period				5 years
Weighted average exercise price of options outstanding		$ 2.32		$ 2.32		$ 2.31
Options exercised				565,001
Exercise price				$ 0.60
Stock options outstanding		11,386,668		11,386,668		13,066,004
Canopy Rivers Corporation Share Based Compensation Plan | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant				33.33%
Canopy Rivers Corporation Share Based Compensation Plan | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant				33.33%
Canopy Rivers Corporation Share Based Compensation Plan | Share-based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of options exercisable on each anniversaries from date of grant				33.33%
Canopy Rivers Corporation Share Based Compensation Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of subordinated voting shares issuable from treasury				10.00%

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Changes in Options Outstanding Under the Omnibus Plan (Details) - shares	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, ending balance	22,471,983
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, beginning balance	32,508,395
Options granted	433,199
Options exercised	(3,176,977)	(3,642,733)
Options forfeited	(7,292,634)
Options outstanding, ending balance	22,471,983

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of the Changes in Omnibus Plan Employee Options (Details)	9 Months Ended
	Dec. 31, 2020$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average exercise price outstanding, beginning balance	$ 34.89
Weighted average exercise price outstanding, ending balance	36.12
Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average exercise price outstanding, beginning balance	34.89
Weighted average exercise price, Options granted	27.20
Weighted average exercise price, Options exercised	11.96
Weighted average exercise price, Options forfeited	40.61
Weighted average exercise price outstanding, ending balance	$ 36.12

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Outstanding Stock Options (Details)	9 Months Ended
	Dec. 31, 2020$ / sharesshares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding	22,471,983
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 10 months 24 days
Options Exercisable	11,935,287
Options Exercisable, Weighted Average Remaining Contractual Life	3 years 5 months 19 days
Range One
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 0.06
Range of Exercise Prices, Upper Range | $ / shares	$ 24.62
Options Outstanding	3,470,359
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 1 month 9 days
Options Exercisable	2,173,398
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 1 month 13 days
Range Two
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 24.63
Range of Exercise Prices, Upper Range | $ / shares	$ 33.53
Options Outstanding	4,669,509
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 3 months 10 days
Options Exercisable	1,309,942
Options Exercisable, Weighted Average Remaining Contractual Life	3 years 7 months 9 days
Range Three
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 33.54
Range of Exercise Prices, Upper Range | $ / shares	$ 36.80
Options Outstanding	5,123,061
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 9 months 3 days
Options Exercisable	3,584,193
Options Exercisable, Weighted Average Remaining Contractual Life	3 years 8 months 4 days
Range Four
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 36.81
Range of Exercise Prices, Upper Range | $ / shares	$ 42.84
Options Outstanding	4,075,747
Options Outstanding, Weighted Average Remaining Contractual Life	4 years
Options Exercisable	2,542,841
Options Exercisable, Weighted Average Remaining Contractual Life	3 years 8 months 26 days
Range Five
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range | $ / shares	$ 42.85
Range of Exercise Prices, Upper Range | $ / shares	$ 67.64
Options Outstanding	5,133,307
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 1 month 24 days
Options Exercisable	2,324,913
Options Exercisable, Weighted Average Remaining Contractual Life	4 years 14 days

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Details) - $ / shares	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.49%	1.60%
Expected volatility	73.00%	73.00%
Expected forfeiture rate	17.00%	13.00%
Black-Scholes value of each option	$ 23.53	$ 14.58
Canopy Rivers Corporation Share Based Compensation Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate		1.61%
Expected volatility		70.00%
Black-Scholes value of each option		$ 0.84
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	5 years	3 years
Minimum [Member] | Canopy Rivers Corporation Share Based Compensation Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)		3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)	7 years	5 years
Maximum | Canopy Rivers Corporation Share Based Compensation Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)		4 years

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of the Changes in RSUs (Details) - RSUs	9 Months Ended
	Dec. 31, 2020shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	883,009
RSUs granted	141,218
RSUs released	(75,478)
RSUs cancelled and forfeited	(132,008)
Ending balance	816,741

Share-Based Compensation - Su_6

Share-Based Compensation - Summary of Share-based Compensation Expense Related to Acquisition Milestones (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ (21)	$ 4,916	$ 5,857	$ 24,311
Canindica
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	604	1,629	1,807	7,925
Spectrum Colombia
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense		3,365		9,765
Other
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ (625)	$ (78)	$ 4,050	$ 6,621

Share-Based Compensation - Su_7

Share-Based Compensation - Summary of Change in Seed Capital Options (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, ending balance	22,471,983
Seed capital loan, options exercised	$ (37,999)	$ (39,149)
Canopy Rivers Corporation Share Based Compensation Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, beginning balance	13,066,004
Options exercised	(565,001)
Options forfeited	(621,668)
Options expired	(492,667)
Options outstanding, ending balance	11,386,668
Seed Capital Options | Canopy Rivers Corporation Share Based Compensation Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, beginning balance	2,805,560
Options exercised	(1,905,559)
Options forfeited	(533,334)
Options expired	(333,333)
Options outstanding, ending balance	33,334
Seed capital loan, beginning balance	$ 140
Seed capital loan, options exercised	(95)
Seed capital loan, options forfeited	(26)
Seed capital loan, options expired	(17)
Seed capital loan, ending balance	$ 2

Share-Based Compensation - Su_8

Share-Based Compensation - Summary of Changes in Canopy Rivers' Stock Options (Details)	9 Months Ended
	Dec. 31, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, ending balance | shares	22,471,983
Weighted average exercise price outstanding, beginning balance	$ 34.89
Weighted average exercise price outstanding, ending balance	$ 36.12
Canopy Rivers Corporation Share Based Compensation Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, beginning balance | shares	13,066,004
Options exercised | shares	(565,001)
Options expired | shares	(492,667)
Options forfeited | shares	(621,668)
Options outstanding, ending balance | shares	11,386,668
Weighted average exercise price outstanding, beginning balance	$ 2.31
Weighted average exercise price, Options exercised	0.60
Weighted average exercise price, Options expired	3.62
Weighted average exercise price, Options forfeited	2.64
Weighted average exercise price outstanding, ending balance	$ 2.32

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Details) - CAD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 5,108,120	$ 7,065,708
Other comprehensive (loss) income	(193,492)	26,495
Income tax expense		(8,000)
Ending balance	4,184,422	6,177,636
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	126,723	41,225
Other comprehensive (loss) income	(110,932)	(50,995)
Ending balance	15,791	(9,770)
Changes of Own Credit Risk of Financial Liabilities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	94,176	(47,130)
Other comprehensive (loss) income	(82,560)	77,490
Income tax expense		(8,000)
Ending balance	11,616	22,360
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	220,899	(5,905)
Ending balance	$ 27,407	$ 12,590

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Net Change in Noncontrolling Interests (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Minority Interest [Line Items]
Beginning balance			$ 5,108,120	$ 7,065,708
Comprehensive income (loss)	$ 75,129	$ (18,280)	(9,183)	(42,730)
Net loss attributable to redeemable noncontrolling interest			9,880	(3,684)
Share-based compensation	19,963	61,679	72,632	241,922
Ending balance	4,184,422	6,177,636	4,184,422	6,177,636
Noncontrolling Interests
Minority Interest [Line Items]
Beginning balance			221,758	285,485
Comprehensive income (loss)			(9,183)	(42,730)
Net loss attributable to redeemable noncontrolling interest			9,880	(4,573)
Share-based compensation			3,389	6,429
Ownership changes			1,696	2,248
Warrants			250
Ending balance	227,790	246,859	227,790	246,859
Canopy Rivers
Minority Interest [Line Items]
Beginning balance			211,086	280,012
Comprehensive income (loss)			4,060	(49,005)
Share-based compensation			2,471	6,182
Ownership changes			1,521	1,361
Warrants			250
Ending balance	219,388	238,550	219,388	238,550
Vert Mirabel
Minority Interest [Line Items]
Beginning balance			7,132	2,422
Comprehensive income (loss)			(8,956)	7,164
Net loss attributable to redeemable noncontrolling interest			5,593	(4,573)
Ownership changes			175
Ending balance	3,944	5,013	3,944	5,013
Bio Steel
Minority Interest [Line Items]
Beginning balance			489
Comprehensive income (loss)			(4,287)	(889)
Net loss attributable to redeemable noncontrolling interest			4,287	889
Share-based compensation			918	247
Ownership changes				887
Ending balance	1,407	245	1,407	245
Other Non Material Interests
Minority Interest [Line Items]
Beginning balance			3,051	3,051
Ending balance	$ 3,051	$ 3,051	$ 3,051	$ 3,051

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Estimated Fair Value on a Recurring Basis (Details) - Fair Value Measurements Recurring - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Assets:
Short-term investments	$ 768,564	$ 673,323
Restricted short-term investments	11,426	21,539
Other financial assets	675,397	195,105
Liabilities:
Convertible senior notes	627,792	450,204
Acreage
Liabilities:
Derivative liability	450,000	250,000
Warrant
Liabilities:
Derivative liability	415,946	322,491
Level 1
Assets:
Short-term investments	768,564	673,323
Restricted short-term investments	11,426	21,539
Other financial assets	1,392	2,596
Level 2
Assets:
Other financial assets	4,871	36
Liabilities:
Convertible senior notes	627,792	450,204
Level 3
Assets:
Other financial assets	669,134	192,473
Level 3 | Acreage
Liabilities:
Derivative liability	450,000	250,000
Level 3 | Warrant
Liabilities:
Derivative liability	$ 415,946	$ 322,491

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 2 Financial Instruments (Details) - Level 2 - Convertible Senior Notes	9 Months Ended
	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Convertible note pricing model
Key inputs	Quoted prices in over-the-counter broker market

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Valuation Techniques and Significant Unobservable Inputs in the Fair Value Measurement of Significant Level 3 Financial Instruments (Details) - Level 3	9 Months Ended
	Dec. 31, 2020
Acreage Financial Instrument Probability of Each Scenario
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Probability weighted expected return model
Significant unobservable inputs	Probability of each scenario
Relationship of unobservable inputs to fair value	Change in probability of occurrence in each scenario will result in a change in fair value
Acreage Financial Instrument Value and Number of Canopy Shares Issued
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Value and number of common shares to be issued
Relationship of unobservable inputs to fair value	Increase or decrease in value and number of common shares will result in a decrease or increase in fair value
Acreage Financial Instrument Intrinsic Value of Acreage
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Probability and Timing of US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Estimated premium on US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value
Acreage Financial Instrument Estimated Premium on US Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Control premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated control premium will result in an increase or decrease in fair value
Acreage Financial Instrument Control Premium
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Market access premium
Relationship of unobservable inputs to fair value	Increase or decrease in estimated market access premium will result in an increase or decrease in fair value
Terr Ascend Exchangeable Shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Put option pricing model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Acreage Hempco Debenture
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
TerrAscend Warrants - March 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Terr Ascend Canada Term Loan
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Terr Ascend Canada Term Loan Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Zea Kal Shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Market approach
Significant unobservable inputs	Share price
Relationship of unobservable inputs to fair value	Increase or decrease in share price will result in an increase or decrease in fair value
Arise Bioscience Term Loan
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Greenhouse Convertible Debenture
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	FinCAD model
Significant unobservable inputs	Share price
Relationship of unobservable inputs to fair value	Increase or decrease in share price will result in an increase or decrease in fair value
Agripharm Royalty Interest and Repayable Debenture Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
TerrAscend Warrants - December 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Probability and timing of US legalization
Relationship of unobservable inputs to fair value	Increase or decrease in probability of US legalization will result in an increase or decrease in fair value
Agripharm Royalty Interest and Repayable Debenture Probability and Timing of U S Legalization
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Future royalties
Relationship of unobservable inputs to fair value	Increase or decrease in future royalties to be paid will result in an increase or decrease in fair value
Warrant Derivative Liability Volatility Of Canopy Growth Share Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Monte Carlo simulation model
Significant unobservable inputs	Volatility of common share price
Relationship of unobservable inputs to fair value	Increase or decrease in volatility will result in an increase or decrease in fair value
Warrant Derivative Liability Volatility of Canopy Growth Share Price, Expected life
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Expected life
Relationship of unobservable inputs to fair value	Increase or decrease in expected life will result in an increase or decrease in fair value
Arise Bioscience Term Loan Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Warrant Derivative Liability Volatility of Canopy Growt Share Price, Discount rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
BioSteel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Future wholesale price and production levels
Relationship of unobservable inputs to fair value	Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value
Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels Discount Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Valuation techniques	Discounted cash flow
Significant unobservable inputs	Discount rate
Relationship of unobservable inputs to fair value	Increase or decrease in discount rate will result in a decrease or increase in fair value
Vert Mirabel Redeemable Noncontrolling Interest Future Wholesale Price and Production Levels
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Significant unobservable inputs	Future wholesale price and production levels
Relationship of unobservable inputs to fair value	Increase or decrease in future wholesale price and production levels will result in an increase or decrease in fair value

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Additional Information (Details) - CAD ($)	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value, transfers of amounts between levels	$ 0	$ 0

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Gross revenue	$ 169,907	$ 135,546	$ 439,823	$ 324,558
Excise taxes	17,379	11,782	41,613	33,699
Net revenue	152,528	123,764	398,210	290,859
Other Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	53,723	33,384	128,746	75,770
CANADA | Medical Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	15,349	14,765	45,935	41,965
International | Medical Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	21,505	18,701	59,170	47,287
Business to Business | Recreational Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	59,106	53,454	157,709	120,556
Business to Consumer | Recreational Cannabis Revenue
Disaggregation Of Revenue [Line Items]
Gross revenue	$ 20,224	$ 15,242	$ 48,263	$ 38,980

Revenue - Additional Informatio

Revenue - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Revenue From Contract With Customer [Abstract]
Allowance for estimated returns and price adjustments	$ 3,750	$ 5,343	$ 10,900	$ 46,070
Liability for estimated returns and price adjustments	$ 7,140		$ 7,140		$ 17,586

Other Income (Expense), Net - S

Other Income (Expense), Net - Schedule of Other Income (Expense), Net (Details) - CAD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Other Income And Expenses [Abstract]
Fair value changes on other financial assets	$ 281,359	$ (77,300)	$ 385,219	$ (188,122)
Fair value changes on liability arising from Acreage Arrangement	(303,000)	(30,000)	(249,849)	(265,190)
Fair value changes on convertible senior notes	(75,498)	6,726	(107,778)	202,566
Fair value change on warrant derivative liability	(193,998)	82,512	(93,455)	749,258
Fair value changes on acquisition related contingent consideration	(3,066)	4,718	39,803	3,078
Interest income	7,310	12,348	19,078	51,529
Interest expense	(1,030)	(2,240)	(3,708)	(4,611)
Foreign currency loss	710	(767)	(10,290)	(9,176)
Gain on acquisition/disposal of consolidated entity		61,775		61,775
Other (expense) income, net	(3,354)	191	(126)	(483)
Other income (expense), net	$ (290,567)	$ 57,963	$ (21,106)	$ 600,624

Acreage Arrangement and Amend_2

Acreage Arrangement and Amendments to Cbi Investor Rights Agreement and Warrants - Additional Information (Details) $ / shares in Units, $ in Thousands	Jun. 24, 2020CAD ($)Vote / shares$ / sharesshares	Jun. 24, 2020USD ($)Vote / sharesshares	Jun. 27, 2019CAD ($)	Jun. 27, 2019USD ($)	Dec. 31, 2020CAD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019CAD ($)	Sep. 23, 2020CAD ($)	Mar. 31, 2020CAD ($)	Apr. 18, 2019CAD ($)$ / sharesshares
Business Acquisition [Line Items]
Debentures bear interest rate per annum					6.10%		6.10%
Debenture maturity in years							10 years	10 years
Warrant expiration date												Nov. 1, 2023
Estimated fair value					$ 193,998,000	$ (82,512,000)	$ 93,455,000		$ (749,258,000)
Tranche A Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares												88,500,000
Warrant price per share | $ / shares												$ 50.40
Tranche B Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares												38,500,000
Warrant price per share | $ / shares												$ 76.68
Tranche C Warrants
Business Acquisition [Line Items]
Warrants to acquire shares | shares												12,800,000
Tranche B and C Warrants | Second Amended and Restated Investor Rights Agreement and Consent Agreement
Business Acquisition [Line Items]
Number of common stock shares to be repurchased to avoid providing repurchase credit | shares												27,378,866
Value of common stock to be repurchased to avoid providing repurchase credit												$ 1,583,000,000
Derivative liability					0		0
Debenture
Business Acquisition [Line Items]
Gain (Loss) on derivative, Net					(17,120,000)		(40,434,000)
Payments to acquire investments							66,995,000	$ 50,000
Estimated fair value										$ 26,561,000
Additional payment upon satisfaction of certain conditions								$ 50,000
Warrant
Business Acquisition [Line Items]
Derivative, financial liability					415,946,000		415,946,000				$ 322,491,000
Estimated fair value					(193,998,000)	82,512,000	(93,455,000)		749,258,000
Maximum | Second Amended and Restated Investor Rights Agreement and Consent Agreement
Business Acquisition [Line Items]
Share repurchase credit limit												$ 1,583,000,000
Acreage
Business Acquisition [Line Items]
Aggregate payment	$ 49,849,000	$ 37,500	$ 395,190,000	$ 300,000
Gain (Loss) on derivative, Net					(303,000,000)	$ (30,000,000)	(249,849,000)		$ (265,190,000)
Acreage | Acreage Financial Instrument
Business Acquisition [Line Items]
Derivative, financial liability					$ 450,000,000		$ 450,000,000				$ 250,000,000
Acreage | Maximum
Business Acquisition [Line Items]
Number Of Fixed And Floating Shares Issued | shares	32,700,000	32,700,000
Acreage | Subordinate Voting Shares | Fixed Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.7	0.7
Acreage | Subordinate Voting Shares | Floating Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.3	0.3
Acreage | Proportionate Voting Shares | Fixed Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	28	28
Acreage | Proportionate Voting Shares | Floating Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	12	12
Acreage | Multiple Voting Shares | Floating Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.3	0.3
Acreage | Multiple Voting Shares | Fixed Multiple Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.7	0.7
Acreage | Class E Subordinated Voting Shares | Fixed Shares
Business Acquisition [Line Items]
Common stock shares conversion ratio	0.3048	0.3048	0.5818	0.5818
Acreage | Class D Subordinated Voting Shares | Floating Shares
Business Acquisition [Line Items]
Minimum call price | $ / shares	$ 6.41
Acreage | Class F Multiple Voting Shares | Fixed Multiple Shares
Business Acquisition [Line Items]
Voting Rights, Votes Per Share | Vote / shares	4,300	4,300

Segment Information - Additiona

Segment Information - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020CAD ($)Customer	Dec. 31, 2019CAD ($)Customer	Dec. 31, 2020CAD ($)SegmentCustomer	Dec. 31, 2019CAD ($)Customer	Mar. 31, 2020CAD ($)
Segment Reporting Information [Line Items]
Number of operating segments | Segment			2
Property, plant and equipment	$ 1,148,338		$ 1,148,338		$ 1,524,803
Customer Concentration Risk | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Concentration risk customer number of customers | Customer	1	1	1	1
Non Canada
Segment Reporting Information [Line Items]
Property, plant and equipment	$ 462,083		$ 462,083		$ 499,059
Revenue	$ 61,468	$ 43,029	$ 155,126	$ 100,436

Segment Information - Summary o

Segment Information - Summary of Financial Information for Canopy Rivers (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Segment Reporting Information [Line Items]
Cash and cash equivalents	$ 824,960	$ 1,303,176
Prepaid expenses and other current assets	78,979	85,094
Other financial assets	682,595	249,253
Other long-term assets	5,357	22,636
Other liabilities	(157,079)	(190,660)
Noncontrolling interests	(227,790)	(221,758)
Total Canopy Growth Corporation shareholders' equity	$ 3,956,632	$ 4,886,362
Canopy Rivers
Segment Reporting Information [Line Items]
Ownership percentage	27.00%	27.00%
Cash and cash equivalents	$ 37,995	$ 46,724
Prepaid expenses and other current assets	5,839	11,598
Investments in associates	5,113	50,543
Other financial assets	250,532	146,812
Other long-term assets	23,260	22,058
Other liabilities	(38,389)	(2,771)
Noncontrolling interests	(219,388)	(211,086)
Total Canopy Growth Corporation shareholders' equity	$ 64,962	$ 63,878

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Terrascend - Subsequent Event	Jan. 13, 2021USD ($)shares
Subsequent Event [Line Items]
Acquired Shares Of Common Stock | shares	1,072,450
Payments to acquire businesses, net of cash acquired | $	$ 10,500